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INTRAVENOUS ADMINISTRATION OF PERFLUOROCARBON EMULSIONS AS A
NON-RECOMPRESSION THERAPY FOR DECOMPRESSION SICKNESS
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Decompression sickness (DCS) results from a sudden decrease in ambient pressure
leading to super-saturation of tissues with inert gas and subsequent bubble formation
within both tissues and blood. Perfluorocarbons (PFC) are able to dissolve vast amounts of
non-polar gases. The administration of intravenous (I.V.) PFC emulsions reduce both
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morbidity and mortality of DCS, but the mechanism of this protective effect has not yet
been demonstrated.
Juvenile Dorper cross sheep between 16 and 24 kg (n=31) were anaesthetized and
instrumented for physiological monitoring, the administration of I.V. fluids and sampling
of arterial and mixed venous blood. Animals were placed in a hyperbaric chamber and
compressed to 6.0 atmospheres absolute for 30 minutes, then rapidly decompressed. Upon
chamber exit animals were randomly assigned to receive 6cc/kg of either PFC or saline
control over 5 minutes beginning immediately after chamber exit. They were also
randomized to receive one of 4 breathing gases post-chamber: 100% O2, 80/20 N2/O2,
50/50 HeO2, or 80/20 HeO2. Blood samples were drawn at 5, 10, 15, 30, 60, and 90
minutes to examine whole-body oxygenation. Respiratory gases were monitored and
recorded in real-time using mass spectroscopy to examine nitrogen washout.
PFC administration increased arterial oxygen content (16.30±0.27 vs. 14.75±0.25
mL/dL, p<0.0001), oxygen delivery (14.83±0.28 vs. 13.44±0.25 mL/minute/kg, p=0.0004),
and tissue oxygen consumption (3.37±0.14 vs. 2.76±0.13 mL/minute/kg, p=0.0018) over
saline control, but did not increase mixed venous oxygen content (12.45±0.26 vs.
11.74±0.24 mL/dL, p=0.0558) or extraction ratio (0.23±0.012 vs. 0.21±0.011, p=0.1869).
PFC administration lowered the plateau of the curve, increasing the amount of
nitrogen washout vs. saline control (22.22±1.566 vs. 15.98±1.380 mmHg, p= 0.0074).
Breathing 80/20 HeO2 increased the decay constant of the curve, increasing the rate of
washout vs. breathing 100% O2 (0.03176±0.001044 vs. 0.03096±0.0009402, p=0.5777).

xvii
PFC improves whole-body oxygenation after severe DCS and increases the amount
of nitrogen washout. Although the effects of both PFC and 80/20 HeO2 breathing were
statistically significant the magnitude of the nitrogen washout effect is quite small, and
unlikely to be clinically significant. Thus it is likely that the improved oxygenation is
responsible for the previously-observed therapeutic effects of PFC in treating DCS.

CHAPTER 1
GENERAL INTRODUCTION
A Short History of Diving
Breath-Hold Diving
The first human entry into the world beneath the sea was performed using breathhold diving. Exactly when and where this first took place has been lost to the ages, but
there are archaeological claims that Neanderthals may have dived for food. We cannot be
sure if they were diving, or rather were harvesting shellfish by wading at low tide(33, 125).
We do know that by 4500 BC, diving had developed from limited and fear-filled
excursions into a thriving industry that supplied the communities with shells, food, and
pearls(33, 125).
From those early times until now fishermen have used breath-hold diving to harvest
products from the sea as diverse as fish, shellfish, pearls, shells, and sponges. Breath-hold
diving was the only method available to access anything deeper than a few feet beneath the
surface up until the nineteenth century when helmet diving equipment was developed(33,
125). Breath-hold diving is still used today. Not only is it a recreational and competitive
sport, but also used as a traditional fishing method by groups such as the Ama diving
women of Japan and Korea, and pearl divers of the Tuamoto Archipelago(88, 125, 134).
Originally the male divers were fishermen while the female divers collected shells and
seaweeds that are important to Korean and Japanese cuisine. More recently diving duties
have been restricted to the women while the men serve as tenders. This change has been
1
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attributed by some to greater endurance of the women in cold water, while others pay
homage to the traditional folklore that diving reduces the virility of males(134).
Diving also has a long history of being used for strategic purposes. Divers are
known to have been involved in military operations as far back as the Trojan Wars (11941184 BC). Divers were used to sabotage enemy ships by boring holes in the hull below the
waterline or cutting anchor ropes(33, 125). Divers were also used in the construction of
underwater defenses to protect ports from attacking fleets(33, 125). Similarly, attackers
would employ divers to remove obstructions.
In North America in the sixteenth, seventeenth and eighteenth centuries, skilled
native divers were able to descend to depths of 30 metres and remain submerged for up to
15 minutes. The Spaniards exploited these native divers’ abilities to harvest pearls, salvage
sunken ships, and even to smuggle goods past customs(33, 125). Demand for such divers
was very high, indicated by their value on the slave market where prices of up to 150 gold
pieces were paid(33, 125)
Diving Equipment
The earliest diving equipment to emerge was the snorkel. These simple breathing
tubes made from reeds or bamboo were developed in many different parts of the world.
This simple device allows a diver to breathe air from the surface with his or her head
underwater. Writings from Aristotle imply that the Greeks used snorkels, though exactly
what for is not clear(33, 106, 107, 125). Columbus also reported that the North American
natives used snorkels for hunting waterfowl. They would submerge themselves and breathe
through a reed while approaching birds floating on the water, and were then able to capture
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the birds with nets, spears, and even with their bare hands(33, 106, 107, 125). Similar
methods were also used by the Australian aborigine to hunt wild duck. Snorkels, however,
do have serious limitations. Respiratory dead space increases with snorkel length. In
addition, deeper dives place a greater load on the respiratory muscles. Thus, snorkels are
not useful deeper than 1-2 feet(33, 106, 107).
Once these limitations were noted, the snorkel spawned the idea of a diver carrying
a gas supply with them. An Assyrian drawing dated 900 BC is believed by some to picture
an early diving set(33, 107, 125). The drawing depicts a man with a tube in his mouth and
the tube connected to a bladder or bag. That such diving sets were not in use centuries later
suggests that either this arrangement did not work well, or that the above interpretation
could be incorrect, and that what is depicted is, in fact, something more akin to a float or
life preserver(33, 107, 125). Leonardo da Vinci also developed ideas for diving sets. His
sketches depict not only breathing equipment, but fins as well(33, 106, 107, 125). In one
sketch he illustrates a long snorkel, which would not have worked well. In another idea he
wrote of, and sketched ideas for providing a diver with a ‘wine skin to contain the breath’.
This is most likely the first design of a self-contained breathing apparatus(33, 106, 107,
125). These sketches by da Vinci appear tentative, so it is most likely safe to assume that
there was no practical diving equipment being used in Europe in da Vinci’s time(33, 106,
107, 125).
Diving bells were the first successful method of allowing divers to remain at depths
greater than could be reached with a snorkel and for durations longer than they could hold
their breath. A diving bell consists of a chamber, weighted so it could sink and open at the
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bottom, in which one or more people could be lowered under water. The early use of
diving bells was limited to short durations in shallow water. The air contained within the
bell would not support life for extended periods and its compression when submerged
would limit the depth to which the bell could be lowered(33, 106, 107, 125). Use of this
type of diving bell dates back to the mid-to-late 15th century(33, 106, 107, 125). A giant
step forward was developed in 1691 by Sir Edmund Halley, after whom the comet is
named, when he patented a diving bell which could be re-supplied with air in barrels(33,
106, 107, 125). Weighted barrels of air were hauled from the surface and the air could be
released into the bell. This development led to the more widespread use of diving bells for
tasks such as salvage, treasure recovery, and construction. Dives to depths of 20 metres for
durations as long as 90 minutes were recorded using this apparatus(33, 106, 107, 125).
Similar diving bells, developed earlier and which probably served as the basis for Halley’s
idea and patent, were used in Sweden for salvage. Between 1659 and 1665 divers were
able to salvage 50 bronze canons weighing over 1000 kg each from the warship Vasa
which sank in 30 metres of water in Stockholm harbour. The guns were recovered by
divers in diving bells assisted by ropes from the surface(33, 106, 107, 125). That this was
accomplished is truly amazing. It would be a difficult task now, even with the best of
modern equipment.
During the second half of the 18th century air pumps were developed that were both
reliable and powerful enough to pump air against the pressures experienced by divers(33,
106, 107, 125). These pumps led to the development of what are now called ‘open
helmets’ for diving. In 1819 Augustus Siebe, a German coppersmith living in London,
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developed a diving rig consisting of a copper helmet riveted to a leather jacket. Air would
be pumped into the helmet, but there was no way to control the amount of air entering the
suit. Excess air would simply bubble out of the jacket at the waist(33, 88, 107). Siebe’s
original suit was quite successful, and was used in the salvage of the British warship
H.M.S. Royal George(33, 88, 107). Its greatest shortcoming was that if the diver should
fall, or if the pump or hose should leak it would quickly fill with water, be difficult to get
out of, and the diver would most likely drown(33, 88, 107). Siebe continued his innovative
design of diving apparati, and by 1837 he had developed a waterproof, full-body suit
which could be bolted to a breastplate and helmet(33, 88, 125). With the emergence of this
suit the diver could safely work in any position because the entire body was enveloped in
the suit. With the suit now being a closed environment, inlet and exhaust valves were
incorporated to allow the divers to regulate their buoyancy. This design was so successful
that it remains essentially unchanged today. The United States Navy Mark V deep sea
diving suit, which was in use up until 1986, is almost an exact copy of Siebe’s original
diving suit, with some refinement in materials and improvement in the valves(88).
Following the development of the diving suit it became possible for divers to dive
to ever greater depths, and to remain at such depths for longer durations than had been
possible with previous equipment. These deeper, longer dives were not accompanied by
what we would think of today as appropriate decompression, and decompression sickness
(DCS) was being noted in more and more divers(88, 125).
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Decompression Sickness
The first recorded instance of what would now be referred to as DCS was recorded
in 1670 by Sir Robert Boyle. In what is now thought of as a landmark experiment in
alternobaric physiology, Boyle placed a viper in a vacuum chamber and was able to
generate symptoms of DCS. In his journal he noted “I once observed a Viper furiously
tortured in our Exhausted Receiver … that had manifested a conspicuous Bubble moving
to and fro in the waterish humour of one of its eyes”(12, 88). In this experiment Boyle
recorded that a rapid decrease in ambient pressure could result in the production of gas
bubbles in body tissues.
The earliest report of symptoms which are now believed to have been DCS in
humans dates back to the 1840’s. The British warship H.M.S. Royal George sank at the
Spithead anchorage near the Isle of Wight, and the wreck was a danger to navigation.
Divers were employed to clear the wreck, and Colonel Pasley, the commander of the
operation, noted symptoms of rheumatism and over-fatigue in many of his divers. These
symptoms were attributed to dampness and cold, so divers were provided with fresh, dry
undergarments. Other divers suffered paralysis which was attributed to zeal and overexertion(88, 125, 169). It is most likely that these men were suffering from DCS,
especially given that their dives exceeded the now-accepted safe diving limits by a factor
of 3(125, 169).
The first records of DCS as such in humans come from a French mining engineer
named Triger. Coal mines below the level of the water table were pressurized with air in
order to keep the water out. In 1841 Triger noticed that some of the miners suffered cramps
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and muscle pains after leaving the compressed air environment of the mine(125, 169). By
1854 DCS was beginning to be understood. Pol and Watelle, two physicians in the employ
of the Douchy Coal Company of Douchy, France began a systematic investigation of the
symptoms experienced by caisson workers. They noticed that this disease was universally
associated with leaving the compressed air environment, and noted that “one pays only on
leaving”(88, 132). Pol and Watelle were also the first to notice that a return to the
compressed air environment was effective in alleviating symptoms, and that younger men
of 18 who had “not reached their greatest mature physical strength” suffered less from the
symptoms of DCS than did men in their mid-30’s “who were in their prime”(88, 132).
Over the next 30 years several small steps were made in the understanding of DCS.
Boyle’s original experiments were repeated in 1857 by Hoppe-Seyler, at which time he
described the obstruction of pulmonary blood vessels by bubbles, and noted that the heart
was unable to adequately pump blood under these conditions(77, 169). He also suggested
that the intravascular release of gas bubbles he had observed might be the mechanism
underlying some of the cases of sudden death observed in caisson workers and divers.
Hoppe-Seyler was also the first to suggest recompression as a therapy for DCS(77, 169). In
1869, Le Roy de Mericourt, a French naval surgeon, reported on an occupational illness he
observed amongst sponge divers in the Mediterranean which was attributed to the
breathing of compressed air. He equated this with the illness observed in caisson workers
and other divers(92, 125). The first review of compressed-air sickness research was
conducted by Freidburg in 1872. He collected descriptions of symptoms of workers who
received insufficient decompression after exposure to high pressure. He also compared the
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clinical course of severe and fatal cases of DCS to that of the venous air emboli
occasionally seen in obstetrics and surgery(125). He believed that rapid decompression
resulted in the release of gas which had been taken up into tissue during the high-pressure
exposure, and that the blood was filled with gas bubbles which interfered with circulation
in the heart and lungs(125). Soon thereafter in 1873 Andrew Smith described what was
becoming known as ‘caisson disease’ as a disease depending on increased atmospheric
pressure, but always developing after reduction of the pressure(125, 144). This illness, he
noted, was characterized by moderate-to-severe pain in one or more of the extremities and
sometimes in the trunk. In some cases, there may be elements of paralysis which, when
they appear, are most frequently confined to the lower extremities. Cerebral symptoms
such as headache, vertigo, convulsions, and loss of consciousness may also be present(125,
144).
The first rigorous scientific study of DCS was carried out by the French
physiologist Paul Bert and was reported in his seminal book of 1878 entitled La Pression
Barometrique(7, 14, 88, 125). Bert was able to demonstrate that the symptoms of DCS
were associated with bubbles in tissue, that these bubbles were formed during rapid
decompression, and that these same bubbles consisted primarily of nitrogen(7, 88, 125).
Bert also used various concentrations of oxygen to speed decompression, demonstrating
the utility of oxygen breathing for the treatment of DCS, and was the first to propose the
idea of oxygen recompression as a therapy for DCS(7, 125).
The now common slang term ‘the bends’ evolved during the construction of the
Brooklyn Bridge. This term was first noted by the above-mentioned Andrew Smith in 1894
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while engaged as the medical advisor for the Brooklyn Bridge caisson work. The
fashionable ladies of the period assumed a stooped posture while walking termed the
‘Grecian bend’. When the workers emerged from the caissons afflicted by DCS, limping
and hunched over from the pain in their legs, hips, and back, their colleagues would chide
them for ‘doing the Grecian bend’(88, 125).
The next major leap forward in the understanding and treatment of DCS came from
an engineer rather than a physician or researcher. In 1889, efforts were underway to drive
railway tunnels under the Hudson River. When the British engineer E. W. Moir took over
as project superintendent the death rate among all workers from DCS was 25%. He erected
a recompression chamber at the work site. Any worker showing signs of DCS was quickly
recompressed and later decompressed at a slower rate. Up until this time, even though it
was understood that recompression was able to alleviate the symptoms of DCS, since
exposure to compressed air had caused the disease in the first place, physicians were loathe
to recommend recompression as a cure(88, 125). Although he admitted in descriptions of
his own work that he believed that his treatment was largely homeopathic, mortality from
DCS amongst his workers decreased. By 1896 the recompression treatment Moir insisted
on had reduced mortality to a mere 1.6% from 25% observed prior to his arrival(88, 111,
169).
By the dawn of the 20th century it was understood that DCS was a product of
nitrogen gas bubbles evolving within the body as a result of decreasing pressure after
exposure to a high-pressure environment. It was also accepted that a return to increased
pressure could relieve the symptoms, but there were no decompression schedules or
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procedures that could be followed to reduce the risk of generating DCS in the first
place(88).
Decompression Planning
Haldanian Theory
In the early part of the 20th century there was a great deal of controversy regarding
exactly how divers and caisson workers should be decompressed(165, 169). It was
generally believed that the best way to avoid DCS was to ascend to the surface at a slow,
uniform rate. There was no consensus regarding what constituted an appropriately slow
rate(1, 165). The Royal Navy Diving Manual specified an ascent rate of 5 feet/minute,
while the French physiologist Paul Bert was advocating for an ascent rate of 3 feet/minute.
The German physiologists Heller, Mager and von Schrotter recommended an ascent rate of
1.5 feet/minute(165). In spite of all these recommendations, DCS was still alarmingly
common amongst divers and caisson workers(165).
The first step towards safe diving was a product of the work of the Scottish
physiologist John Scott Haldane. His critical supersaturation ratio hypothesis formed the
basis of the first decompression tables. Exactly how Haldane persuaded the Royal Navy to
investigate his hypothesis is not known. Navy submarines were sinking, the divers
salvaging them were at risk, and the little-known fact that his older brother was the
Minister of War may have influenced the decision(4, 165).
By Haldane’s time Bert had established that the signs and symptoms of DCS were
often associated with nitrogen bubbles in blood and tissue(7, 165). He was also struck by
the powerful impact that long exposures at depth had on the appearance of DCS. For
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example a salvage diver working for the Siebbe-Gorman company salvaged £70,000 in
gold bullion from a wreck sitting in 162 feet of seawater (fsw) over the course of 33 safe
dives with 25-minute bottom times. For a single dive he extended his bottom time to 45
minutes. After this dive he developed paralysis from which he never fully recovered(165).
Likewise another diver working for Siebbe-Gorman salvaged silver from several wrecks at
depths ranging from 174 to 180 fsw with bottom times ranging from 8 to 13 minutes. After
approximately 70 safe dives using this profile he extended his bottom time to 40 minutes.
Upon surfacing he experienced great pain and ruptured blood vessels with blood
accumulating under the skin. His condition was so serious that a priest was called and
administered last rites, but he survived and was back working a week later(165).
These cases, and others like them, suggested to Haldane that a diver’s tissues
absorbed nitrogen in a time-dependent manner while under pressure as arterial blood
carried dissolved nitrogen from the lungs to other body tissues. When the diver ascended
and the pressure decreased some excess nitrogen in tissue could be safely tolerated, but too
much would cause bubbles to form and result in DCS(165).
To examine what sort of time-depth combinations could be tolerated Haldane
performed a series of experiments in goats. He exposed them to 2.36 atmospheres absolute
(ATA) for 2 hours and then rapidly decompressed them to surface pressure (1 ATA). This
pressure drop of 1.36 ATA produced DCS in some animals(55, 169). He also found that
the same absolute decrease in pressure of 1.36 ATA from 6 ATA did not produce DCS, but
rather a decrease of 3 ATA was required to cause DCS(55, 169). From this he deduced that
DCS was not a product of an absolute decrease in pressure. Instead, he theorized, DCS was
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caused by a relative decrease in pressure. More specifically he hypothesized that pressure
could be decreased in a 2:1 ratio without causing DCS. Thus, if a dive was conducted to 6
ATA, the diver could safely ascend to 3 ATA where a stop needed to be made or if a dive
were conducted to 4 ATA, the diver could safely ascend to 2 ATA where a stop needed to
be made(55, 169). This is known as the ‘critical ratio’ supersaturation hypothesis and led
to the idea of ‘stage decompression’. From here, Haldane made some assumptions: First,
that the uptake and elimination of nitrogen followed an exponential pattern. Second, that
the body could be represented mathematically using 5 different ‘tissue compartments’ with
nitrogen loading and unloading half-times of 5, 10, 20, 40 and 75 minutes. These ‘tisue
compartments’ are purely mathematical constructs. They do not directly equate to any
tissue in the body. From these data and assumptions Haldane devised the first dive tables.
Haldane’s ‘Table I’ was used for dives to depths of up to 204 fsw with decompression
times up to 30 minutes – see Table 1. This table proved to be very successful and virtually
eliminated DCS, but over time was found to call for decompression stops that were both
deeper and longer than were necessary in practice(165, 169). Haldane’s ‘Table II’ was
used for dives with bottom times exceeding 1 hour requiring over 30 minutes of
decompression. It was found to generate decompression schedules that were insufficient to
prevent DCS(165, 169) – see Table 2.
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Table 1: Table I of appendix IV from J. S. Haldane’s ‘The prevention of
compressed air illness’(55)
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Table 2: Table II of appendix IV from J. S. Haldane’s ‘The prevention of
compressed air illness’(55)
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Neo-Haldanian Developments
As Haldene’s ideas and findings were carried to other countries, including France,
Russia, and the United States, Haldane’s original tables were modified in search of safe
and efficient decompression schedules. The United States Navy found that Haldane’s
original 2:1 supersaturation ratio was too conservative for short dives, limited by nitrogen
accumulation in tissues with short nitrogen loading half-times, producing decompression
schedules that were longer than necessary. At the same time this 2:1 ratio was found not to
be conservative enough for long duration dives where decompression is limited by tissues
with long nitrogen loading half-times, resulting in an unacceptably high number of cases of
DCS(169). These experiences indicated that Haldane’s critical supersaturation ratio was
not fixed at 2:1 under all conditions. Work for the United States Navy by Yarbrough in the
1930’s found that the critical supersaturation ratio was different for each of the
hypothetical tissue compartments in the mathematical model, but also varied with the
duration of exposure, or dive time(169, 187). Subsequent work by Des Granges, Dwyer,
and Workman showed that the critical supersaturation ratio also varied with depth(27, 36,
169, 185). This ultimately led to the replacement of the critical supersaturation ratio with a
series of tables of ‘M values’ by Workman. (169, 185) – see Table 3. These showed the
maximum allowable supersaturation for each of the hypothetical tissue compartments in
the model at each depth. This work represented an enormous leap forward in the
understanding of the physiology of DCS and, with the addition of a 120-minute nitrogen
loading half-time tissue compartment to the model, formed the basis of the 1956 United
States Navy dive tables, which, with a few minor modifications, are still in use today(165,
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169). In fact, the vast majority of dive tables, or decompression tables in use today are
direct outgrowths of Haldanian and neo-Haldanian approaches and understanding.
Table 3: Workman M-values(185). The maximum allowed (absolute) partial
pressure of nitrogen M in a hypothetical tissue compartment characterized by the half-time
τ is defined as follows:
M = M0 + ΔMD
Where M = partial pressure limit for each tissue compartment (τ) in metres of
seawater (msw)
M0 = partial pressure limit at sea-level (zero depth) (msw)
ΔM = increase of M per metre of depth (msw/m)
D = depth (m)
τ (minutes)
5
10
20
40
80
120
160
200
240

M0 (msw)
31.7
26.8
21.9
17.0
16.4
15.8
15.5
15.5
15.2

ΔM
1.80
1.60
1.50
1.40
1.30
1.20
1.15
1.10
1.10

In more recent years as divers have been venturing ever deeper for longer durations
even these neo-Haldanian tables proved to be inadequate. More and more tissue
compartments were needed in the model to produce decompression schedules with
adequate safety. These models grew from the original 5 compartments in Haldane’s model
to as many as 20 with nitrogen loading half-times as long as 1000 minutes for extreme
exposures(169).
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Other Hypotheses
As often happens in any area of research, shortly after Haldane’s pioneering work
dissenting opinions began to appear. In 1912, Sir Leonard Hill produced both experimental
and theoretical evidence questioning the value of stage decompression over continuous,
uniform decompression(67). Hill believed that Haldane’s stage decompression allowed gas
bubbles to form in tissue and then attempted to limit their growth by applying
decompression stops whereas using a slow, linear decompression could prevent bubble
formation altogether. Although Hill’s techniques are now used extensively in
decompression from long duration saturation exposures such as are used in very deep
water by the oil and gas industry, his inability to explain why Haldane’s technique was
able to avoid DCS, combined with the practical value of the ease-of-use of Haldane’s
tables meant that Haldane won out with the British Royal Navy in the early 1900’s(67,
169).
Decades later, in the early 1960’s, Brian Hills & Hugh Le Messurier observed that
Okinawan pearl divers using air as a breathing gas were able to dive to depths of 90 metres
for durations of up to one hour, twice a day, six days per week. These people, as a group,
had accumulated enormous experience. They were working without any preconceived
scientific framework and were eventually able to produce safe decompression procedures.
These procedures were arrived at through trial and error and were very expensive in terms
of lives lost during development. Their procedures required approximately 33% less
decompression time than the United States Navy tables(93). Hills therefore suggested that
DCS develops in the early stages of ascent. He believed that adding deeper decompression
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stops rather than extended shallow stops would decrease the incidence of DCS. A study he
conducted in the United Kingdom demonstrated that this theory was correct. By moving
the conventional 3 metre (m) decompression stop to 6 m, the incidence of decompression
sickness was decreased by 40%(70, 169).
Observations such as these led to Hills postulating a ‘thermodynamic’ model of
DCS and introduced the concept of ‘unsaturation’ to the understanding of bubble
prevention and resolution(69, 71, 72, 75). The concept of unsaturation is best illustrated by
examining representative values for the partial pressures of respiratory gases for a person
under normal atmospheric pressure - see Table 4.

Table 4: Partial pressures of respiratory gases at 1 ATA(174)
Sample
Inspired Air
Expired Air
Alveolar Air
Arterial Blood
Venous Blood
Tissues

O2
(mmHg)
158
116
100
100
40
≤30

CO2
(mmHg)
0.3
32
40
40
46
≥50

Gas Partial Pressure
N2
H2O
(mmHg)
(mmHg)
596
5.7
565
47
573
47
573
47
573
47
573
47

Total
(mmHg)
760
760
760
760
706
700

It is clear from Table 4 that the total gas tension in tissues is less than the ambient
barometric pressure, thus the tissue is ordinarily unsaturated, and others have suggested
that the degree of unsaturation may be higher than the 60 mmHg indicated in Table 4
above(75, 169). The importance of this tissue unsaturation in diving is that an
instantaneous reduction in pressure equal to at least 60 mmHg (an ascent of 2.6 fsw) is
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required before tissues become saturated with gas(70, 75, 169). After this ascent the
alveolar partial pressure of nitrogen is less than the tissue partial pressure of nitrogen so a
pressure gradient is established, and to balance this gradient nitrogen is eliminated from
tissue, re-establishing tissue unsaturation(70, 75, 169). This suggests that the speed at
which gas is taken into tissue or eliminated from tissue is critically important to the
development of DCS. For example, when astronauts are operating outside the space
vehicle in space suits, the suit is pressurized to 0.2-0.3 ATA. In order for astronauts to
operate in this low-pressure environment they must first pre-breathe 100% oxygen for 3
hours to remove nitrogen from their bodies. If the astronaut breathes room air for as little
as 5 minutes after this denitrogenation they will develop DCS at suit pressure(169). Only
the ‘fast’ tissues, those with very short nitrogen loading half-times could be involved in
this sequence. This is likely a result of the fact that several nitrogen gradients are
developed at the same time by the depressurization. Not only is there a gradient from these
‘fast’ tissues to alveolar gas, but there is also a gradient from these ‘fast’ tissues to ‘slower’
tissues, and they will continue to absorb gas from the faster tissues, even after the pressure
has stabilized, until the whole system reaches equilibrium. In this way the ‘fast’ tissues
serve not only as the depot to which nitrogen is added to and removed from the body, but
also as a source of nitrogen to slower tissue compartments, as illustrated in Figure 1.
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Figure 1: Graphical representation of tissue on- and off-gassing.
Nitrogen is loaded into tissues based on the partial pressure to which it is exposed.
This figure represents how N2 would move into and out of theoretical tissue compartments
with half-times ranging from 5 to 520 minutes during and after a dive to 6.0 ATA (165
fsw) for 30 minutes. Notice that gas continues to load into compartments with slower halftimes even after the dive is over. This is because the nitrogen in the faster half-time
compartments moves not only out of the body via the lungs, but into slower half-time
compartments which are less filled.
The next leap in understanding DCS began in 1951 when Harvey postulated the
importance of bubble nuclei in the formation of bubbles in DCS(63). This went largely
unnoticed until 1977 when Yount et al. integrated Harvey’s ideas about bubble nuclei with
the concept of unsaturation(194). This led to new theories about bubble formation and
growth and began a revolution in thinking about decompression planning. Up until this
time all dive tables were based to some degree on the work of Haldane. The one critical
failing of Haldanian and neo-Haldanian approaches is the fact that there is the inherent
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assumption that all gases remain dissolved. If gas should come out of solution and form
bubbles, it is effectively lost to the calculations, despite the fact that it was well-understood
that bubbles were the root of DCS.
Yount proposed that there are stable gas micronuclei that can act as seeds for
bubble growth(194). Greatly simplified, bubble growth is a function of internal pressure
vs. external pressures acting on the bubble. The internal pressure (Pb) is due to the gas
molecules contained in the bubble, and is a product of the combined partial pressures of all
dissolved gases in the immediate environment of the bubble. The external pressures
include the ambient pressure (Pa), tension due to tissue displacement (Pt), and the surface
tension of the bubble (Py). If Pb > Pa + Pt + Py then the bubble will grow, if
Pb < Pa + Pt + Py then the bubble will shrink(169, 194). Bubble growth can follow

decompression when Pb reflects the pressure of gases (especially nitrogen) at a greater
depth and Pa is decreasing. Similarly, bubbles can grow in areas of turbulent blood flow
where Pt is reduced. The effect of Py will vary with the size of the bubble according to the
Law of LaPlace: Py = 2 y

r

where Py = pressure due to surface tension, y = surface tension

and r = radius of the bubble. For large bubbles Py is reduced, and may become negligible.
For very small bubbles Py may become so great as to force the bubble back into
solution(169, 194). Given the above, it is difficult to understand how extremely small
bubbles are able to persist except in protected environments. Further work by Yount
demonstrated that even though bubbles of diameters greater than 1 μm should float to the
surface of standing liquids or gels and bubbles smaller than this should dissolve within a
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few seconds, that there are stable microbubbles present in most liquids and gels which can
act as seeds for the development of DCS(190, 191, 194, 195).
These findings gave birth to a new way of thinking about DCS. Ultimately they
resulted in a radical change in decompression planning – what are now called dual phase
models. These models account for dissolved gas much like neo-Haldanian models do, but
also track free gas in the form of bubbles. They seek to shape a decompression profile in
order to minimize the number of bubbles formed, as well as their total volume(178-181,
188, 191-193). The two best developed models of this type are the Varying Permeability
Model (VMP) and the Reduced Gradient Bubble Model (RGBM)(176-179, 181, 188, 190,
191, 193). These represent the most advanced decompression models currently in use.
These dual-phase models operate fundamentally differently than the dissolvedphase (Haldanian and neo-Haldanian) models. Dissolved-phase models seek to prevent
DCS by removing excess nitrogen as quickly as possible. This is done by ascending to
depths as shallow as is safe, followed by long, shallow decompression stops. Dual-phase
models, on the other hand, seek to minimize the number and, more importantly, the total
volume of bubbles free in circulation. This is achieved by requiring short decompression
stops beginning at depths much greater than dissolved-phase models would recommend.
This keeps the ambient pressure relatively high, promoting gas dissolution out of the
bubbles and elimination via the lungs, resulting in bubble shrinkage. These dual phase
models result in decompression schedules which are both shorter and statistically produce
fewer incidents of DCS(176-179, 181, 188, 190, 191, 193).
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RGBM in particular has been used to plan and execute extraordinary dives which
would not have been possible using dissolved-phase models. For example, on 17
December, 2007 two divers from the Woodville Karst Plains Project, Jarrod Jablonski and
Casey MacKinlay, entered the Turner Kink near Tallahassee, FL. They descended to a
depth of 300 fsw where they entered an underwater cave system. They penetrated an
amazing 11.25 km into the cave system before turning around and exiting the way they
came in. The cave penetration itself required 6 hours, and an additional 14 hours of
decompression time was required before the two divers could exit the water. Neither of
these divers developed any signs or symptoms of DCS(61, 182). This dive would not have
been possible prior to the advent of dual-phase models for decompression planning.
Physiology and Pathophysiology of Decompression Sickness
What is Decompression Sickness?
DCS is a much less well understood phenomenon than researchers in the field
would like people generally to believe. Understanding the physiology and pathophysiology
of DCS is complicated by several factors. Chief among them is the simple fact that a
diagnosis of DCS is entirely based on history and symptoms. There exist no medical tests
to either rule in or to rule out DCS. Furthermore, DCS is a stochastic phenomenon. If ten
people were all subjected to the same dive profile designed to produce some symptoms of
DCS, some would suffer from DCS symptoms while others would not. Among those that
developed symptoms, there would be a wide range of presentations from mild joint pain to
serious neurological symptoms such as parasthesia and paralysis - see Table 5. Similarly, if
one person were subjected to the same dive profile in the example above on ten different
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occasions, they would most likely develop symptoms of DCS on some occasions, and not
on others, and just as above, the symptoms they develop are likely to vary from one
exposure to the next. At this time there doesn’t exist a clear understanding of all the factors
that contribute to DCS, let alone how they affect the onset and development of DCS. For
these reasons DCS remains very difficult to predict in any terms other than statistical
probabilities.
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Table 5: Frequency of signs and symptoms in 935 cases of decompression
sickness(138)
Sign or Symptom

Localized pain
Numbness or paresthesia
Muscular weakness
Skin rash
Dizziness or vertigo
Nausea or vomiting
Visual disturbances
Paralysis
Headache
Unconsciousness
Urinary disturbances
Dyspnea (“chokes”)
Personality change
Agitation or Restlessness
Fatigue
Muscular twitching
Convulsions
Incoordination
Equilibrium disturbances
Localized edema
Intestinal disturbance
Auditory disturbance
Cranial nerve involvement
Aphasia
Hemoptysis
Subcutaneous emphysema

Number of
Instances
Within 935
Cases
858
199
193
140
80
74
64
57
37
26
24
19
15
13
12
12
11
9
7
5
4
3
2
2
2
1

Percentage of
Instances Within
935 Cases
91.8
21.2
20.6
14.9
8.5
7.9
6.8
6.1
3.9
2.7
2.5
2.0
1.6
1.3
1.2
1.2
1.1
0.9
0.7
0.5
0.4
0.3
0.2
0.2
0.2
0.1

Number of
Instances
Manifested
Initially
744
41
8
42
24
8
14
2
5
6
0
4
0
0
2
0
0
0
0
0
0
0
0
0
0
0

Percentage of
Initial
Manifestations
76.6
4.3
0.8
4.4
2.5
0.8
1.4
0.2
0.5
0.6
0.4
0.2
-
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The study of the physiology and pathophysiology of DCS is also complicated by
the fact that DCS is a symptomatic diagnosis. Firstly, it is unethical to conduct randomized
trials in people, deliberately subjecting them to a condition which could cause permanent
injury or death. Likewise the invasive measurements needed to best understand what is
happening in the midst of DCS are also not ethical for human use. Secondly, studies in
animals are complicated by the simple fact that animals are not able to report on their
symptoms. This makes it very difficult to ascertain to what degree the symptoms generated
in animal experiments mimic what is observed in humans. None the less, great strides have
been made in understanding the physiology and pathophysiology of DCS over the last 340
years, as was touched upon above. These advances will now be elaborated upon and
examined from the perspective of physiology, rather than that of history.
The consensus in the hyperbaric community is that DCS is the result of the
formation of gas bubbles in tissue and anatomic spaces unsuited to the presence of gas
upon decompression, however, the presence of such gas bubbles does not inevitably lead to
DCS(34, 45, 170). Gas bubbles in tissue may produce no symptoms at all or may produce
symptoms ranging from pruritis, fatigue, or joint and muscle soreness to permanent
paralysis, convulsions, and death(34). The term ‘decompression sickness’ is generally used
to refer to the pathologic response to the development of bubbles in tissue and blood, while
the term ‘decompression illness’ is used as a general term to denote any injury or illness
which is a consequence of a reduction in ambient pressure, including, but not limited to
DCS, barotraumas, as well as both arterial and venous gas emboli.
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DCS, as defined above, is a product of a rapid decrease in ambient pressure(34). At
equilibrium the amount of gas dissolved in any given tissue is proportional to the partial
pressure of that gas to which the tissue is exposed according to the physical principal
known as Henry’s law. The gas partial pressure to which tissues are exposed is primarily a
product of ambient pressure and the gas mix being breathed. When ambient pressure
decreases, bubbles will form in the tissue unless the gas can either be taken up by tissue, as
would be the case with O2 or CO2, or carried down a concentration gradient and ultimately
equilibrate with the gas partial pressures in the alveoli, from which they can be exhaled
through the lungs, as would be the case for inert gases(34). When this reduction of ambient
pressure is sufficiently gradual, the removal of excess gas proceeds safely(34, 55, 67).
When ambient pressure is decreased both too much and too rapidly it is believed that gas
bubbles form and result in the symptoms of DCS, but exactly how and where in the body
these bubbles form remains poorly understood(32, 170). What is understood is that part of
the mechanism of injury in DCS is the mechanical effects of these bubbles, be that the
compression and distortion of tissue surrounding the growing bubble, or obstruction of
blood flow by bubbles lodged in arterioles, capillaries or venules(34, 169, 170).
How and Why Bubbles Form
Water, and thus water-based fluids, can tolerate very high levels of supersaturation
before bubbles begin to form de novo within the water itself. In fact, in pure water,
supersaturation itself will not produce bubbles until this supersaturation is approximately
1000 ATA. That is to say, if water exposed to room air is normally saturated with 0.79
ATA of nitrogen, then the nitrogen partial pressure would need to exceed 790 ATA in
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order to generate de novo bubble formation as a result of supersaturation alone(66, 169).
Since DCS can develop with supersaturations considerably less than this, there must be
other mechanisms involved in addition to supersaturation by itself. There are two
mechanisms for the formation of bubbles, with much lower degrees of supersaturation
necessary, which are believed to be at play in the body. The first of these is the process by
which bubbles can grow from pre-existing, stable micronuclei already present in
tissue(115, 169, 189). With any sort of imperfection in a surface, very small pockets of gas
can develop and remain stable in environments which, without the stabilizing effects of the
crevice in which they reside, would collapse and dissolve. The presence of such stable
‘micronuclei’ has been previously demonstrated by Yount et al(190, 191, 194, 195). When
supersaturation of the liquid develops, gas molecules can diffuse into these micronuclei
and they will expand, bulging out of the crevice into the surrounding liquid. Surface
tension at the gas-liquid interface tends to oppose this growth, but it will continue as long
as the liquid is sufficiently supersaturated for gas to diffuse into the forming bubble. When
the forming bubble reaches a critical size, surface tensions will pinch off the budding
bubble and release it into the liquid leaving the micronucleus behind to repeat the process
so long as the state of supersaturation persists(115, 169, 189). This is the process by which
bubbles are released from carbonated beverages and why the bubbles appear to stream
from certain points on the wall of the glass. This is illustrated in figure 2 below.
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Figure 2: Nucleation of bubbles from pre-existing micronuclei with
decompression.
Stable gas micronuclei exist within microscopic imperfections in surfaces. When
the surrounding liquids are supersaturated with gas, gas will dissolve into the micronucleus
causing it to grow and bud out into the liquid. Once the bubble reaches a critical size
surface tension effects will cause the bubble to be pinched off and released into the liquid
leaving the micronucleus behind to repeat the process.
The second mechanism likely at play is called tribonucleation, or cavitation
nucleation. Local areas of very low pressure are created within the body by several factors
including vertical motion in areas of turbulent blood circulation, and the shearing forces
created within joints as solid structures move away from each other. The extremely low
pressures generated in these environments can exceed 1000 ATA below ambient pressure,
and is sufficient to allow for the spontaneous formation of bubble nuclei, which can then
grow as gas from the supersaturated blood and tissue diffuses into the bubble(109, 166,
169). This same process can take place even when tissue is not supersaturated with gas.
The formation and collapse of bubbles formed by tribonucleation is responsible for the
sound of knuckles cracking(34, 165, 169).
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Where Bubbles Form and Where They Are Found
Where such bubbles form is even less well understood than how they form. In
theory, bubbles can form in any liquid environment, including within cells, in extracellular
fluid spaces, and within the blood and lymphatic circulations, as well as in cerebrospinal
fluid (CSF). The intracellular formation and growth of bubbles would result in membrane
rupture and functional loss similar to what is observed with the formation of intracellular
ice crystals in frostbite. Bubbles have been observed to form and grow in decompressed
hen’s eggs, but unicellular organisms and erythrocytes in suspension have proven to be
very resistant to intracellular bubble nucleation(62, 65, 121). None the less, it has been
inferred that intracellular gas bubbles do form in mammals from observed mitochondrial
membrane abnormalities and intracellular bubbles have been observed in some adipocytes
of rapidly decompressed rodents(6, 46). Some of the space-occupying lesions observed in
myelin sheaths may have begun as intracellular bubbles(6, 40, 46, 158). Although
intracellular bubbles probably do form, their clinical importance is likely overshadowed by
other events(34).
Bubbles may also form in the extracellular, extravascular space. In fact, the earliest
report of DCS commented on the presence of a bubble in the aqueous humour of a viper’s
eye(12). Similar observations have also been recorded in dogs(22). Likewise, bubbles have
been reported to be present in the urine, CSF, and tear film of acutely decompressed
animals(55, 156). It is unlikely that bubbles formed in these extracellular fluids produce
any clinical symptoms(34). During the development of the first deep water diving tables,
numerous holes were found to be present in fixed tissue of the spinal cords of goats that
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had developed DCS(55, 60). Since that time many other investigators have reported the
presence of empty spaces in the white matter of fixed spinal cords that compress and
distort surrounding structures after decompression(40, 108, 122, 158). These spaces were
found to be more common in decompressed animals than in control animals, thus it is
unlikely that they were purely fixation artifacts(40, 108). They appeared to compress
surrounding structures suggesting that the empty spaces were growing bubbles(40, 108). It
is difficult to determine if the origin of these bubbles was intracellular, extracellular, or
intravascular due to the distortion of surrounding tissues. Gas bubbles that appear to be
extracellular have been observed in the peripheral nerve myelin of decompressed guinea
pigs, suggesting that the spinal cord lesions may, indeed, have been extracellular in
origin(34, 47).
The most common location where gas bubbles either form, or end up is in the
intravascular space. Intravascular bubbles produce symptoms by interfering with blood
circulation. Arterial gas bubbles are more likely to result in serious pathologic
consequences than are venous bubbles(34, 170). Intravascular gas bubbles have been
directly observed in vivo after decompression in the arteries and veins of the hamster cheek
pouch, in the spinal epidural veins, posterior spinal arteries, and cranial arteries and veins
of dogs(13, 15, 47, 56, 101). There have also been numerous reports of intravascular gas
bubbles in humans after fatal DCS(24, 64, 123). The in vivo occurrence of intravascular
bubbles in humans is inferred from the observation of abnormal ultrasound signals using
Doppler flow meters and ultrasound scans(5, 38, 82). These techniques are only able to
detect moving bubbles and small bubbles are difficult to distinguish from solid

32
emboli(105). The Doppler signal is auditory and is usually recorded and later graded by
experienced observers. This type of analysis lends itself to bias if the observers are aware
of the experimental conditions. Any movement of the transducer is also very likely to
generate signal artifacts. Despite these limitations, Doppler ultrasound is an accepted tool
in DCS research(34).
Intravascular bubbles associated with DCS are most often confined to the venous
side of the circulation. Arterial bubbles are rarely observed, but when present they usually
accompany serious symptoms of DCS(34). It is unlikely that bubbles form directly in the
arteries since the relatively high arterial blood pressure opposes their formation and the
arterial blood, having just passed through the lungs, has inert gas tensions close to ambient
pressure(34). Arterial bubbles are usually a result of one of two causes: pulmonary
barotrauma or right-to-left shunts, either in the heart or in the lungs. Pulmonary barotrauma
is most often a product of air trapped within the broncho-alveolar tree expanding on
decompression. This results in tearing of the lung parenchyma and vasculature and air
being forced into the pulmonary veins with overpressurizations as small as 29.5 kPa or 4.2
psi(136, 186). Right-to-left shunts in the heart usually take the form of atrial septal defects,
such as a patent foramen ovale. Approximately 20-30% of the human population have
defects such as this(157). Several studies have indicated that patent foramen ovale is much
more common among divers that develop severe DCS than in the general population(113,
183). This suggests that atrial septal defects are commonly associated with severe DCS,
but whether or not they increase the risk of developing DCS, and to what degree, is
unknown(34). The lungs are ordinarily a very efficient filter of the bubbles present in the
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venous circulation after decompression(16, 73). However massive numbers of bubbles in
the venous circulation can overwhelm the ability of pulmonary capillaries to filter out such
microemboli(16, 73). Large numbers of bubbles also lead to the opening of pulmonary
arteriovenous shunts, as well as increased pulmonary arterial pressure, both of which
contribute to passage of bubbles through the lungs into the arterial circulation(18, 114).
These mechanisms are likely involved in cerebral DCS as it has been observed that after
severe DCS in dogs known to be without atrial septal defects, the first bubbles to appear in
the cerebral circulation appear in the arteries(34)
Non-Mechanical Effects of Bubbles
Bubbles causing distortion of tissues and obstructing blood flow would be injurious
in and of itself, even if the body did not react in any way to the presence of the bubbles.
However, blood is a highly reactive, living tissue which is primed to respond to any
deviation from its normal environment(34). The presence of bubbles in circulation is
sufficient to trigger many of these responses(34). Endothelial cells are key players in the
regulation of blood coagulation and the regulation of microcirculatory blood flow.
Endothelial cells are often damaged by the passage of bubbles, even bubbles small enough
to pass through the vessel without lodging and obstructing blood flow(74, 164). The blood
gas interface is capable of denaturing proteins because the hydrophobic portions of the
proteins will have a lower free energy when surrounded by air than by blood plasma(95).
This protein denaturation can lead to the accumulation of free fat globules and bubble
formation can provoke the release of free fatty acids from cell membranes(34, 64, 96). The
accumulation of such products can result in the formation of fat emboli, which have been
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observed in several pathologic studies of DCS, and may contribute to the central nervous
system damage associated with DCS(34, 64, 96).
The presence of bubbles is also able to activate coagulation and complement
systems. Bubbling of air through cell-free blood plasma has been shown to decrease
clotting time, presumably through the activation of the contact system activator known as
Hageman factor(57, 58). Hageman factor activates the intrinsic pathway for thrombin
formation and activates the system for kinin formation(41, 119). This results in pain,
vasodilation, edema formation, leukocyte chemotaxis, and activation of the plasma
fibrinolysis system(41, 119). The net effect of the activation of these systems is
progressive clotting and subsequent ischemia at and around the site of the bubble(41, 119).
These activated factors are also distributed systemically and likely contribute to leukocyte
trapping in the lungs and systemic reactions to decompression such as fatigue(34).
Complement activation by bubbles has been noted in rabbit serum and rabbits depleted of
complement have been found to be resistant to DCS(20, 171, 173). While complement
activation is certainly seen with DCS, exactly how it contributes to the pathology of DCS
is poorly understood due to conflicting reports in the literature regarding the correlation of
activated complement with severity of signs and symptoms of DCS(76, 153, 172).
Human studies have shown increased packed cell volume and decreased platelet
counts after decompression(127). These findings are consistent with the development of
edema and activation of thrombin, which would further impair blood flow in the
microcirculation by increasing blood viscosity(34). Electron microscopy studies have
shown that leukocytes and platelets adhere to both circulating bubbles and damaged
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endothelium(128). These cells have also been shown to accumulate in areas of low blood
flow after arterial air embolism in the brain(35, 59, 118). Leukocyte depletion has been
shown to reduce the severity of neurophysiologic damage induced by cerebral air
embolism(35, 59, 118).
Bubbles, it would appear, are the root cause of the signs and symptoms of DCS.
The injury induced by the presence of bubbles is not limited to direct mechanical
interaction of bubbles with tissue. The presence of bubbles, particularly in the blood, will
also activate multiple biochemical pathways that ultimately lead to thrombosis and edema,
as discussed above. This can have detrimental effects which outlast the presence of the
bubbles that triggered the activation in the first place.
Perfluorocarbons
Perfluorocarbons and Oxygen
The emergence of perfluorocarbon (PFC) emulsions as medical therapeutics is
largely a product of the dangers of viral transmission associated with blood transfusion in
the early-to-mid 1980’s(147). With the advent and refinement of viral marker testing in the
1990’s, the risk of viral transmission decreased dramatically, but there remain risks
associated with blood transfusion that can never be eliminated such as ABO and Rh
incompatability, graft-vs.-host disease, volume overload, and immunosuppression(147). In
part as an effort to deal with these risks, the development of safe and efficacious
intravenous (I.V.) oxygen therapeutics, or ‘blood substitutes’, continues to be investigated.
Perfluorocarbon emulsions are one of the lines of products currently being investigated.
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Perfluorocarbons are a synthetic class of small molecules composed of linear or
cyclic carbon backbones in which the carbon atoms have been fully substituted with
fluorine or other halogens(154, 155). These compounds were originally developed during
the Manhattan Project for use as insulators in nuclear piles(141, 154). Perfluorocarbons
also serve as the building blocks of products such as Teflon (polytetrafluoroethylene;
DuPont, Wilmington, DE) and Scotchgard (fluorochemical products; 3M, St. Paul,
MN)(141, 154). During the 1950’s and 1960’s there was a great deal of research involving
PFCs which ultimately culminated in the above-mentioned Teflon. During this research it
was surreptitiously noted that PFCs were able to dissolve vast amounts of non-polar gases
such as oxygen, carbon dioxide, and nitrogen(117). Unlike hemoglobin, which carries
oxygen by binding it to the ferrous center in the heme moiety, PFCs carry oxygen
passively(147, 154). Perfluorocarbons dissolve oxygen in proportion to the pO2 to which
they are exposed(147, 154). Therefore the more the pO2 can be increased, the more oxygen
can be carried(147, 154). Many PFCs in their pure liquid form can dissolve 50-60 mL of
oxygen per 100 mL of PFC at a pO2 of 760 mmHg (See table 6)(147).
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Table 6: Oxygen solubility of various perfluorochemicals(49).
Compound
Perfluorodihexyl ether
Perfluorodibutyl sulfur tetrafluoride
Perfluorotriisobutylamine
Perfluoro-(N-ethylmorpholine)
Perfluoro-N,N-dipropylmethylamine
Perfluorotriethylamine
Perfluoro-N-methylpiperidine
Perfluoro-N-methylmorpholine
Perfluoro-N,N-dimethyl-N-hexylamine
Perfluoro-N-butylmorpholine
Perfluoro-4-(N,N-dimethyl-2-aminoethyl)-morpholine
Perfluoropentyl ether

O2 Solubility (mL O2/100 mL of
compound at PO2 760 mmHg)
55.42
48.02
44.37
50.10
52.60
53.86
41.33
37.57
51.51
50.59
45.07
49.67
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The medical world quickly picked up on this observation and in 1966 it was first
demonstrated that a PFC liquid could be used to supply oxygen in organ perfusion
models(51). In the mid-to-late 1970’s experimental work began on liquid breathing
systems(21). Goldfish, mice, rats, and even cats were submerged in different liquid
environments(21). Mice and goldfish were placed in low-viscosity silicone oils with
oxygen solubilities approximately 1.5 times the oxygen content of whole blood(21). Mice
were able to survive in this environment, but only if the temperature was kept below 18 °C,
and they all died within 10 minutes of being removed from the oil(21). Goldfish were able
to survive for weeks in silicone oils bubbled with oxygen(21). Perfluorocarbons proved to
be a much more satisfactory medium for liquid breathing. An oxygen electrode placed in
the brain of a mouse prior to immersion showed the same level of tissue oxygenation while
breathing oxygenated perfluorobutyltetrahydrofurans as when breathing room air(21).
After removal from the PFC the mice could survive for weeks(21).
Perfluorocarbon Emulsions
Around the same time, pure PFCs were being emulsified for possible use as ‘blood
substitutes’. Several emulsions were developed using the PFCs perfluorotributylamine and
perfluorodecalin(48). It was found that these emulsions, when properly prepared, could be
used to perform a total blood volume exchange in rats, reducing their hematocrit below
1%, and that these rats could survive for weeks after such transfusions(48). These so-called
‘bloodless’ rats were found to be able to carry out their normal functions, regenerate
normal blood cells and plasma proteins, and grow and develop normally(48). It was
believed at the time that such rats could prove to be powerful research tools(116, 129-131,
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140, 159). At least initially, they were lacking all plasma proteins, and thus any desired
combination of plasma proteins could be generated simply by adding them to the rat(116,
129-131, 140, 159). Such models have been used sporadically to study various conditions
such as cyanide toxicity, carbon monoxide toxicity, transcapillary transport, as well as in
imaging studies where the refractive effects of haemoglobin need to be eliminated(116,
129-131, 140, 159).
Thus far only a single PFC emulsion has been approved by the FDA for use in
humans, the first-generation PFC emulsion Fluosol-DA(20%) (Green Cross Corp, Osaka,
Japan), and then only for the prevention or treatment of distal myocardial ischemia during
coronary angioplasty(147). Although it was fairly successful in this application, its use was
cumbersome. The development of angioplasty systems which allow coronary flow to
continue, combined with a side effect profile which included complement release and
activation, hypotension, white cell depression, and uptake by the reticuloendothelial
system resulting in hepatomegaly and splenomegaly resulted in Fluosol-DA(20%) never
gaining enough popularity among clinicians for widespread use(29, 90, 91, 147).
Ultimately it was withdrawn from the market. Newer second- and third-generation PFC
emulsions are currently under development. These products contain higher concentrations
of PFCs, smaller particle sizes, and different emulsifiers which do not provoke such
aggressive immune responses(147). The PFC emulsions currently under development
provoke mild flu-like symptoms such as malaise, muscle aches, and a mild fever, as well
as transient thrombocytopenia 3-4 days after administration of the PFC emulsion(19, 52,
141, 145, 146, 155). However these mild side-effects are quite tolerable, especially in the
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light of the much-improved oxygen carrying capacity of these newer products(19, 52, 141,
145, 146, 155).
Perfluorocarbons and Decompression Sickness
PFC emulsions have the ability to enhance the transport of gases other than oxygen.
All non-polar gases are soluble in PFCs and of particular interest is nitrogen. In pure PFCs
nitrogen may be up to 10,000 times more soluble than in plasma(147). Nitrogen is the
primary component of room air and as such can become a problem in many surgical
procedures. Microscopic air emboli are a common problem in cardiopulmonary bypass,
and larger air emboli are serious complications of neurosurgical, orthopaedic, and some
gynaecological procedures(17, 53, 85, 120, 126). Animal studies have shown that PFC
emulsions administered preoperatively can greatly reduce, or prevent entirely, the harmful
effects of venous air embolism, intracoronary air embolism, and cerebral arterial gas
embolism(110, 149, 150, 162). Data obtained using early formulations of PFC emulsions
suggests strongly that the capacity of the PFC emulsion to dissolve and carry nitrogen is
one of the likely mechanisms by which this protection is afforded(110, 149, 150, 162).
It is the ability of PFC emulsions to dissolve and remove larger amounts of nitrogen
that first attracted attention in the realm of DCS research. Since excess nitrogen trapped in
tissue is believed to be the root cause of DCS, a therapy which could either act as a sink for
that nitrogen, increasing the effective volume of distribution sufficiently that bubbling is
limited, or that can speed the elimination of excess nitrogen from the body, again, limiting
bubble formation and growth, is an obvious target for DCS research. The use of PFCs for
the prevention or treatment of DCS has taken many different forms. Likely the most
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esoteric of these was the enteric administration of pure, degassed PFCs(142). Although this
idea was patented over 12 years ago, there has been no active research on this topic since.
Far more common is the idea that either I.V. PFC emulsions or pure, oxygenated PFC
liquids as breathing media can be used to treat or prevent DCS. The ideal situation is to
prevent DCS altogether. Several studies have demonstrated that breathing liquid,
oxygenated PFCs during hyperbaric exposures followed by rapid or even explosive
decompression is able to prevent the development of DCS, while air-breathing control
animals exposed to the same compression/decompression produced large numbers of
animals with severe DCS(50, 89, 103, 175). Diving performed using liquid breathing
would most likely make DCS irrelevant, but there are enormous hurdles which would need
to be overcome. The respiratory muscles are not designed to move a high-viscosity liquid
in and out of the lungs and would quickly be exhausted by doing so. This would
necessitate a closed-circuit ventilator capable of pumping the PFC in and out of the lungs,
as well as adding oxygen to, and removing carbon dioxide from the breathing liquid. There
are also tremendous psychological factors which would need to be overcome. Inhaling a
liquid causes a sensation of drowning and produces panic(2, 11). These factors combine to
make what may be an ideal solution to the problem very impractical.
Research has instead focused primarily on the I.V. use of PFC emulsions to treat or
prevent DCS. Lundgren et al. demonstrated that I.V. PFC emulsions could greatly enhance
nitrogen washout at surface pressure while breathing oxygen(99). Although no
compression/decompression was associated with this experiment, it demonstrated that I.V.
PFC emulsions might be able to prevent DCS when used prophylactically to remove the
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nitrogen normally present in the body prior to a dive. Unfortunately this sort of treatment is
unlikely to be useful in the real world. Mahon et al. found that although I.V. PFCs
administered at depth enhanced nitrogen elimination, they also enhanced acute oxygen
toxicity manifested by seizure activity(104). Since acute oxygen toxicity is of much greater
immediate danger to a diver in the water, I.V. PFC emulsions are unlikely to be
administered before a diver has left the water.
Intravenous PFC emulsions used after exit from the water in order to treat DCS,
rather than to prevent it, appear much more likely to be clinically useful. Several studies
have demonstrated that the administration of I.V. PFC emulsions after the onset of severe
DCS is able to dramatically reduce morbidity and mortality in a variety of species(23, 31,
100, 151). That the administration of I.V. PFC emulsions can reduce both the severity of
DCS symptoms and reduce the lethality of severe DCS is now generally accepted within
the hyperbaric community, but the mechanism of this protective effect has not yet been
demonstrated.
The studies described in this dissertation were purposed to examine two possible
mechanisms for the protective effects afforded by I.V. PFC administration in severe
cardiopulmonary DCS: First, that the intravenous administration of PFC emulsions acutely
following decompression is able to increase oxygen delivery at the whole-body level, and
presumably to prevent or lessen hypoxic death or injury of tissue to which there is little or
no blood flow as a result of bubble obstruction. Second, that the intravenous administration
of PFC emulsions acutely following decompression is able to increase the removal of
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excess nitrogen from the body, thus relieving the obstructions caused by intravascular gas
bubbles.

CHAPTER 2
INTRAVENOUS PERFLUOROCARBON EMULSIONS INCREASE
WHOLE-BODY OXYGENATION AFTER SEVERE
DECOMPRESSION SICKNESS
Introduction
Breathing compressed air increases the amount of nitrogen dissolved in body
fluids(54, 112, 135). Factors such as depth, thus the ambient pressure, and the duration of
the dive are the primary determinants of the amount of excess nitrogen absorbed(26, 54,
112, 135). As a diver ascends and ambient pressure decreases it is possible for the
dissolved gas tensions in tissue to exceed ambient pressure. This supersaturated state leads
to the formation and growth of free gas bubbles, resulting in venous gas emboli (VGE) and
possible arterial gas emboli (AGE)(26, 32). It is believed that these bubbles within the
vasculature are the root cause of decompression sickness (DCS)(26, 32). There are likely
multiple pathophysiological mechanisms at play in DCS including impairment of
microcirculation by inert gas bubbles, increased blood viscosity, damage to endothelium,
and activation of complement. The physiochemical discontinuity of the gas-blood interface
can also denature proteins promoting the release of fatty acids from cell membranes
leading to the formation of fat emboli(26, 32). When intravascular bubbles obstruct
capillaries or venules, it often leads to ischemia followed by reperfusion induced oxidative
tissue damage(37).
Perfluorocarbon emulsions (PFCs) are intravenous emulsions of fluoridated
hydrocarbons within phospholipid micro-particle micelles(155). PFCs have been
44
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developed in medicine as intravenous oxygen therapeutics(155). PFCs accomplish this in a
way which is fundamentally different from how whole blood transports the majority of its
oxygen content. Oxygen, or any other gas, carried by PFCs is not bound, as oxygen is to
hemoglobin, rather it is dissolved in the PFC itself. PFC, because of its non-polarity, can
dissolve up to 60 volume percent oxygen(117). Plasma can only dissolve 0.034 volume
percent but whole blood at 14 gm/dl hemoglobin can chemically bind up to 21 volume
percent oxygen. The oxygen dissolved in PFC is all available for tissue usage whereas that
chemically bound by hemoglobin is restricted (usually only 23% can be released for
metabolism). Microcirculatory changes such as edema, vasospasm, white cell activation
and vessel plugging result in decreased erythrocyte delivery of oxygen to watershed
neurons, yet plasma flow may continue without red cells(160). PFC, due to its extremely
small particle size (~0.1-0.4 µm) can be delivered in this trickle-flow of plasma(9, 137,
155). Plasma flow oxygen delivery by PFCs is enough to keep tissue alive, as seen with
Fluosol DA-20%, a first generation PFC which reduced myocardial infarction and
garnered FDA approval(86, 87).
PFC is also effective in treating DCS, AGE and VGE(23, 31, 147-149, 151, 196).
Using a saturation dive model with direct ascent to the surface, Dromsky et al. found that
the administration of I.V. PFC while breathing 95% oxygen was able to decrease the
lethality of this decompression insult, decrease the incidence of DCS, and decrease the
number of neurological events(31). Similarly it was found that I.V. PFC can improve
outcomes after massive VGE, cerebral AGE, and coronary AGE(148-150). The
administration of I.V. PFC has also been shown to increase nitrogen washout through the

46
lungs after VGE(196). Clearly PFC administration is of benefit in the treatment of
decompression illnesses, but the exact mechanism of this benefit has not yet been
elucidated. Is this benefit a result of the PFCs ability to increase nitrogen washout, and
thus, presumably, to remove the bubbles obstructing circulation faster? Is it a product of
improving the oxygen supply and thus metabolic state of tissue to which blood flow and
oxygen supply has been disturbed? Is it some combination of both of these events? The
research described here was designed to investigate the effect of I.V. PFC emulsions
administered acutely after surfacing on whole-body oxygenation in an ovine model of
severe DCS.

Materials and Methods
All animal experiments performed for this project were done in strict accordance
with the National Institutes of Health (NIH) “Guide for the Care and Use of Laboratory
Animals” and were approved by both the Department of Defense (DoD) and the Virginia
Commonwealth University Institutional Animal Care and Use Committee (IACUC).
Juvenile Dorper cross sheep of either sex (Robinson Services, Inc., Mocksville, NC)
weighing 14-24 kg were housed in United States Department of Agriculture (USDA)- and
Association for Assessment and Accreditation of Laboratory Animal Care International
(AAALAC)-approved facilities in social flocks with free access to food and water on a 12hour light/dark cycle. Sheep were allowed a minimum of 3 days for acclimatization and
veterinary inspection prior to their use in any experiment.
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Sheep Instrumentation and Preparation
Prior to the experiment sheep were muzzled for a period of 48 hours in order to
prevent access to food and providing free access to water while remaining with the
remainder of their flock in order to limit animal stress. Sheep were initially sedated with
ketamine/xylazine (20.0/2.0 mg/kg I.M.) and the animal was placed supine on the surgical
table. All animals were promptly intubated with a 9.0 mm internal diameter (I.D.) cuffed
endotracheal tube (Hudson RCI, Temecula, CA) and ventilated with 50/50
nitrogen/oxygen using a Siemens 900C servo ventilator (Siemens Corp., New York, NY)
set to a tidal volume of approximately 10 mL/kg adjusted to maintain arterial pCO2 at 40
mmHg ± 5 mmHg. An orogastric tube fashioned from TYGON® R-3603 tubing (SatinGobain Performance Plastics Corp., Akron, OH) was advanced into the rumen to allow for
fluid drainage and to allow gas accumulated in the gut during the air dive to vent upon
decompression. A MAC® 2-port introducer sheath (Arrow International Inc., Reading, PA)
was placed in the right external jugular vein to allow for the administration of fluids and
the anesthetic cocktail. Once I.V. access was secured, administration of the triple drip
anesthetic cocktail (ketamine/xylazine/guaifenesin 2.0/0.1/50.0 mg/mL in 5% dextrose)
was begun immediately at 1.0-2.0 mL/kg/hr titrated to maintain a surgical plane of
anesthesia using a Harvard Apparatus PHD 2000 programmable syringe pump (Harvard
Apparatus, Holliston, MA). The right femoral artery was canulated with an 18 gauge (G)
femoral arterial catheter (Arrow International Inc., Reading, PA) for monitoring of arterial
pressure (AP) and arterial blood sampling. The right femoral vein was canulated with a 4
French (Fr) double lumen catheter (Arrow International Inc., Reading, PA) for the
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administration of the anesthetic cocktail while inside the hyperbaric chamber and for the
administration of the treatment drug after exiting the hyperbaric chamber. The left femoral
vein was canulated for the placement of a 7.5 Fr CCOmbo® continuous cardiac output
(CCO) pulmonary artery catheter to allow for CCO monitoring, central venous (CVP) and
pulmonary arterial pressure (PAP) monitoring, and central venous blood sampling.
Respiratory gases were continuously monitored using an MGA 1100 respiratory mass
spectrometer (Perkin-Elmer, Norwalk, CT). Following surgical manipulations all animals
were allowed to stabilize for a minimum of 30 minutes. After stabilization animals were
weaned off the ventilator until capable of spontaneously breathing prior to being placed
inside the hyperbaric chamber.
Inclusion/Exclusion Criteria
At the end of the stabilization period all animals were required to meet certain
inclusion criteria prior to being weaned off the ventilator and placed in the hyperbaric
chamber. The inclusion criteria were as follows: mean arterial pressure above 60 mmHg,
arterial pO2 above 200 mmHg, arterial pH 7.45 ± 5, arterial pCO2 40 ± 5 mmHg. All
animals not meeting the above inclusion criteria were excluded from the study and
euthanized.
Sheep Dry Dive Procedures
All sheep that met the study inclusion criteria (n=31) were weaned off the ventilator
until capable of breathing spontaneously, then disconnected from all monitoring equipment
and placed into a Reimers Systems model #17-48-100 Research Hyperbaric Chamber
(Reimers Systems, Inc., Springfield, VA). During the dry dive procedures all animals
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breathed room air and general anesthesia was maintained using a continuous infusion of
triple drip as described above. All sheep were subjected to the following dive profile:
Beginning at 1.0 ATA the chamber was compressed at a rate of 1.0 ATA/minute to a
pressure of 2.0 ATA. From 2.0 ATA the chamber was compressed at a rate of 2.0
ATA/minute to a pressure of 6.0 ATA (165 feet of seawater (fsw), or 608 kilopascals
(kPa)). The pressure of 6.0 ATA was maintained for 27 minutes, after which sheep were
immediately decompressed to 1.0 ATA at a rate of 2.0 ATA/minute.
Post-Decompression Monitoring
Upon complete decompression (considered time=0) all animals were quickly
removed from the hyperbaric chamber and all monitoring equipment was reconnected. At
this point animals were randomized to receive I.V. infusion of either 6.0 mL/kg Oxycyte®
PFC (n=15) (Synthetic Blood International, Costa Mesa, CA) or saline control (n=16) and
one of four breathing gases; 100% oxygen (n=8), 80/20% nitrogen/oxygen (n=8), 50/50%
helium/oxygen (n=7), or 80/20% helium oxygen (n=8). Animals were randomized using a
block randomization scheme such that for every 8 experiments performed one animal fell
into each of the 8 treatment groups, but the order within each block was random.
Neuromuscular blockade with I.V. pancuronium (0.1 mg/kg) given acutely post-chamber
was necessary in order to accurately measure respiratory gases with the mass spectrometer.
All animals were monitored for 90 minutes after decompression, during which time both
arterial and mixed venous blood samples were drawn and analyzed using a Radiometer
OSM 3 Hemoximeter and a radiometer ABL 700 blood gas analyzer (Radiometer America,
Westlake, OH) at 5, 10, 15, 30, 60 and 90 minutes after decompression. Data from all
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instruments was recorded directly to hard drive storage using the BioPac system and
Acqknowledge v. 3.90 software (BioPac Systems, Inc. Goleta, CA) After 90 minutes all
animals were euthanized.
Later offline analyses were performed in order to determine arterial and mixed
 ), tissue oxygen
venous blood oxygen content ( CaO2 , Cv O2 ), oxygen delivery ( DO
2
 ), and oxygen extraction ratio (ER). The following formulae were used
consumption ( VO
2

for the calculations:
Arterial oxygen content:
CaO2 = (1.34 × Hb × SaO2 ) + [(0.0031× PaO2 × α ) + (0.01997 × PaO2 × β )] (1)
Mixed venous oxygen content:
Cv O2 = (1.34 × Hb × Sv O2 ) + [(0.0031× Pv O2 × α ) + (0.01997 × Pv O2 × β )] (2)
Oxygen delivery:
 = [CO × (CaO2 × 10)]
DO
2
weight

(3)

Oxygen consumption:
 = CO × [(CaO2 − Cv O2 ) × 10]
VO
2
weight
Extraction ratio:

VO
2
ER =
(5)

DO2

(4)

Where CaO2 = arterial oxygen content in mL/dL
Cv O2 = mixed venous oxygen content in mL/dL
Hb = hemoglobin concentration in mg/dL
S aO2 = arterial oxygen saturation fraction
PaO2 = arterial oxygen tension in mmHg

= oxygen delivery in L/minute/kg body weight
DO
2

 = oxygen consumption in L/minute/kg body weight
VO
2
ER = extraction ratio
CO = cardiac output in L/minute
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0.0031 = oxygen solubility coefficient in plasma in mL/dL
0.01997 = oxygen solubility coefficient in PFC in mL/dL
α = blood fraction of circulation volume
β = PFC fraction of circulating volume

Statistical Methods
Unless otherwise stated all data were analyzed using repeated-measures analysis of
variance (ANOVA) controlling for cardiac index, PFC administration, and breathing gas
administered, followed by Least Squares Means Student’s t-test, as appropriate, to
determine if treatment and control groups were significantly different. Data are presented
as Least Squares Means ± Standard Error. Differences considered statistically significant
with p-values of less than 0.05. All statistical calculations were performed using the
statistical software JMP 7 from SAS Institute (Cary, NC).

Results
One-way ANOVA performed on baseline data obtained during the stabilization
period post surgery and pre-dive, controlling for breathing gas, indicated that there were no
statistically significant differences between the PFC-treated group and the saline controls
on any of the variables of interest (PFC vs. saline - cardiac index (indexed to body
weight)(CI): 91.88 ± 0.65 vs. 100.84 ± 0.63 mL/minute/kg, p=0.3305; CaO2 : 15.72 ± 0.53
vs. 14.67 ± 0.51 mL/dL, p=0.1680; Cv O2 : 12.28 ± 0.48 vs. 10.95 ± 0.47 mL/dL, p=0.0610;
 : 14.35 ± 0.90 vs. 14.65 ± 0.87 mL/minute/kg, p=0.8097; VO
 : 3.09 ± 0.34 vs. 3.71 ±
DO
2
2

0.33 mL/minute/kg, p=0.1931; ER: 0.22 ±0.019 vs. 0.25 ± 0.019, p=0.2895).
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After compression/decompression it was found that, with regards to CI, the
repeated measures ANOVA was significant as a whole model (F=14.91, df=5, p<0.0001)
as well as with regards to perfluorocarbon administration (F=17.99, df=1, p<0.0001) and
with regards to time (F=7.06, df=1, p=0.0087). Using Student’s t-test cardiac index was
found to decrease over the course of the experiment and it was found to be significantly
lower in the PFC-treated group vs. the saline control group (82.66 ± 3.46 vs. 102.61 ± 3.18
mL/minute/kg, p<0.0001 – see figure 3). Due to the significant effect PFC administration
had on CI, CI was controlled for in all further analyses.
The analysis of arterial oxygen content, as a whole model, was found to be
significant (F=10.89, df=6, p<0.0001). This model was also found to be significant with
respect to PFC administration (F=17.31, df=1, p<0.0001) and with respect to time (F=8.61,
df=1, p=0.0038). Using Student’s t-test It was found that CaO2 was significantly higher in
the PFC-treated group vs. the saline group (16.30 ± 0.27 vs. 14.75 ± 0.25 mL/dL,
p<0.0001) and increased over the course of the experiment – see figure 4.
With regard to mixed venous oxygen content, it was found that the whole model
was significant (F=7.68, df=6, p<0.0001), but neither PFC administration (F=3.71, df=1,
p=0.0558) nor time (F=1.16, df=1, p=0.2822) had a significant effect. Student’s t-test
indicated that Cv O2 was not significantly different in the PFC-treated group vs. the saline
control group (12.45 ± 0.26 vs. 11.74 ± 0.24 mL/dL, p=0.0558) – see figure 5.
 , it was found that the whole model was significant (F=104.27,
With regards to DO
2

df=6, p<0.0001) and that PFC administration had a significant effect (F=12.97, df=1,
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p=0.0004), but time did not (F=3.46, df=1, p=0.0648). Student’s t-test showed that the
 over the saline control group (14.83 ± 0.28 vs. 13.44
effect of the PFC was to increase DO
2

± 0.25 mL/minute/kg, p=0.0004) – see figure 6.
 . The whole model was significant
Similar effects were observed with regard to VO
2

(F=26.22, df=6, p<0.0001), and both PFC (F=10.11, df=1, p=0.0018) and time (F=9.13,
df=1, p=0.0029) were observed to have significant effects. Student’s t-test showed that
 vs. saline control (3.37 ± 0.14 vs. 2.76 ± 0.13 mL/minute/kg,
PFC increased VO
2
 was found to increase over the course of the experiment – see figure 7.
p=0.0018) and VO
2

When extraction ratio, defined as


VO
2

 , was analyzed it was found that the
DO
2

whole model was significant (F=4.94, df=6, p<0.0001). The effect of PFC was found not
to be statistically significant (F=1.76, df=1, p=0.1869) while the effect of time was
significant (F=5.85, df=1, p=0.0167). PFC administration did not significantly increase the
ER over saline control (0.23 ± 0.012 vs. 0.21 ± 0.011, p=0.1869), but ER did increase over
the course of the experiment – see figure 8.
Discussion and Conclusions
As has been seen before in other split-hoofed animal models, I.V. administration of
PFCs resulted in decreased CI in this model(152). In the previous work conducted in pigs,
pulmonary hypertension was reported to be the cause of the observed decrease in CI and
similar observations were made here(152). When analysed using the same repeated
measures ANOVA model described above pulmonary arterial pressure was found to be
nearly doubled in the PFC-treated animals vs. the saline control (27.10 ± 1.12 vs. 15.50 ±
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1.12, p<0.0001). This suggests that the problem of pulmonary hypertension leading to
decreased CI will likely be present in all split-hoofed species.
It is clear from this study that I.V. PFC administration results in an increase in
CaO2. In the PFC-treated group arterial oxygen content is elevated nearly 11% over
control. Even if the oxygen carried directly by the PFC is removed from the calculations,
arterial oxygen content is still significantly higher in the PFC-treated vs. the saline-treated
group (15.87 ± 0.26 vs. 14.73 ± 0.24 mL/dL, p=0.0019), so it would appear that PFC does
more than simply carry more oxygen. Exactly what PFC is doing, in addition to its own
nascent oxygen carrying ability, is unclear. Further analysis using the repeated measures
ANOVA model showed both PaO2 and SaO2 were significantly lower in the PFC-treated
vs. saline-treated group (200.03 ± 10.77 vs. 238.72 ± 9.90 mmHg, p=0.0109 and 93.52 ±
0.89 vs. 97.39 ± 0.81 %, p=0.0021, respectively). Hemoglobin (Hb) was elevated in the
PFC-treated group vs. the saline control after compression/decompression (12.22 ± 0.17
vs. 10.72 ± 0.15 mg/dL, p<0.0001) but not when baseline results were analysed using oneway ANOVA (11.19 ± 0.38 vs. 10.61 ± 0.37 mg/dL, p=0.2931). It is possible that the
presence of the PFC is inducing the release of erythrocytes from the spleen or other
storage, accounting for the higher Hb, and thus the higher CaO2 in the PFC-treated group.
Likewise, the observation that PFC administration results in increases in both
 and VO
 of 10% and 22%, respectively, demonstrates that the PFC is able to not only
DO
2
2

increase the amount of oxygen present in the blood, but is able to improve tissue access to
that oxygen. This suggests that the mechanism of I.V. PFC improving tissue oxygenation
is not simply its ability to dissolve and carry greater quantities of oxygen, but that it
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facilitates oxygen delivery to cells. This may take the form of the PFC extravasating in
capillary beds, taking dissolved oxygen with it. Alternatively the PFC emulsion particles,
being approximately 1/100th - 1/1000th the size of an erythrocyte, may be able to pass
through blood vessels where red cell flow has been blocked by bubbles, but a trickle flow
of plasma remains(31, 151) – see figures 9 and 10. In this case the small amount of oxygen
carried in the PFC may be sufficient to keep tissue viable which otherwise might succumb
to hypoxic injury. More interestingly, PFC particles may act as a bridge, of sorts,
facilitating the movement of oxygen from erythrocytes out into cells where it is needed.
This possibility has very intriguing implications. As shown above, the amount of oxygen
actually dissolved in PFC is relatively small. Hemoglobin binding oxygen remains the
dominant mechanism for oxygen transport. Once in capillary beds the greatest impediment
to oxygen offloading from hemoglobin into tissue is the plasma(133). Oxygen is very
insoluble in plasma, and much more soluble in PFC. In this case the PFC would act almost
as a transport vessel for oxygen, ferrying it from erythrocytes to tissue, a mechanism
somewhat akin to facilitated diffusion across cell membranes. These possible mechanisms
should be explored further in future studies.
It is clear from these results that improved tissue oxygenation at a whole-body level
is likely responsible for at least a portion of the beneficial effects offered by the I.V.
administration of PFC emulsions after severe decompression sickness.
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Figure 3: The effect of perfluorocarbon administration on cardiac index.
The effect of the administration of PFC emulsions, when the effects of time and
breathing gas are controlled for, is to significantly decrease cardiac index vs. the saline
control group (82.66 ± 3.46 vs. 102.61 ± 3.18 mL/minute/kg, p<0.0001).
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Figure 4: The effect of perfluorocarbon administration on arterial oxygen content.
The effect of the administration of PFC emulsions, when the effects of time,
breathing gas, and CI are controlled for, is to significantly increase CaO2 vs. the saline
control group (16.30 ± 0.27 vs. 14.75 ± 0.25 mL/dL, p<0.0001).
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Figure 5: The effect of perfluorocarbon administration on mixed venous oxygen
content.
When the effects of time, breathing gas, and CI are controlled for, PFC has no
significant effect on Cv O2 vs. the saline control group (12.45 ± 0.26 vs. 11.74 ± 0.24
mL/dL, p=0.0558).
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Figure 6: The effect of perfluorocarbon administration on oxygen delivery.
The effect of the administration of PFC emulsions, when the effects of time,
 vs. the saline
breathing gas, and CI are controlled for, is to significantly increase DO
2
control group (14.83 ± 0.28 vs. 13.44 ± 0.25 mL/minute/kg, p=0.0004).
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Figure 7: The effect of perfluorocarbon administration on oxygen consumption.
The effect of the administration of PFC emulsions, when the effects of time,
 vs. the saline
breathing gas, and CI are controlled for, is to significantly increase VO
2
control group (3.37 ± 0.14 vs. 2.76 ± 0.13 mL/kg/minute, p=0.0018).
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Figure 8: The effect of perfluorocarbon administration on extraction ratio.
When the effects of time, breathing gas, and CI are controlled for, PFC has no
significant effect on ER vs. the saline control group (0.23 ± 0.012 vs. 0.21 ± 0.011,
p=0.1869).
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Figure 9: Erythrocyte size compared with PFC emulsion particle size.
A cartoon illustrating the relative size of red blood cells (diameter approx 6-8 μm)
compared to Oxycyte® PFC emulsion particle size (approx 0.1-04 μm).
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Figure 10: Perfluorocarbon emulsion particles can pass thrombi which block blood
flow.
A cartoon illustrating that PFC emulsion particles, due to their small size (approx
0.1-0.4 μm), are able to flow past emboli such as bubbles, fat, blood clots, and
constrictions which obstruct the flow of erythrocytes. By moving past such obstructions
PFCs may be able to continue to deliver enough oxygen to tissues with no red cell flow to
stave off hypoxic injury or death.

CHAPTER 3
INTRAVENOUS PERFLUOROCARBON EMULSIONS INCREASE
THE EXTENT, BUT NOT THE RATE WHILE HELIUM-OXYGEN
BREATHING INCREASES THE RATE, BUT NOT THE EXTENT OF
NITROGEN WASHOUT AFTER SEVERE DECOMPRESSION
SICKNESS
Introduction
Breathing compressed air increases the amount of nitrogen dissolved in body
fluids(54, 112, 135). Factors such as depth, and thus the ambient pressure, and the duration
of the dive are the primary determinants of the amount of excess nitrogen absorbed(26, 54,
112, 135). As a diver ascends and ambient pressure decreases, it is possible for the
dissolved gas tensions in tissue to exceed ambient pressure. This supersaturated state leads
to the formation and growth of free gas bubbles resulting in venous gas emboli (VGE) and
possible arterial gas emboli (AGE)(26, 32). It is believed that these bubbles within the
vasculature are the root cause of decompression sickness (DCS)(26, 32). There are likely
multiple pathophysiologic mechanisms at play in DCS including impairment of
microcirculation by inert gas bubbles, increased blood viscosity, damage to endothelium,
and activation of complement. The physiochemical discontinuity of the gas-blood interface
can also denature proteins promoting the release of fatty acids from cell membranes
leading to the formation of fat emboli(26, 32). When intravascular bubbles obstruct
capillaries or venules, it often leads to ischemia followed by reperfusion oxidative tissue
damage(37).
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Perfluorocarbon emulsions (PFCs) are intravenous (I.V.) emulsions of fluoridated
hydrocarbons within phospholipid micro-particle micelles(155). PFCs have been
developed in medicine as intravenous oxygen therapeutics(155). PFCs accomplish this in a
way which is fundamentally different from how whole blood transports the majority of its
oxygen content. Oxygen, or any other gas, carried by PFCs is not bound as oxygen is to
hemoglobin, rather it is dissolved in the PFC itself. PFC, because of its non-polarity, can
dissolve up to 60 volume percent oxygen(117). Plasma can only dissolve 0.034 volume
percent oxygen, but whole blood at 14 gm/dl hemoglobin can chemically bind up to 21
volume percent oxygen. The oxygen dissolved in PFC is all available for tissue usage
whereas oxygen chemically bound by hemoglobin is restricted (usually only 23% can be
released for metabolism). Microcirculatory changes such as edema, vasospasm, white cell
activation and vessel plugging result in decreased erythrocyte delivery of oxygen to
watershed neurons, yet plasma flow continues without red cells(160). PFC, due to its
extremely small particle size (~0.1-0.4 µm) can be delivered in this trickle-flow of
plasma(9, 137, 155). Plasma flow oxygen delivery by PFCs is enough to keep tissue alive,
as seen with Fluosol DA-20%, a first generation PFC which reduced myocardial infarction
and garnered FDA approval(86, 87).
PFC is also effective in treating DCS, AGE and VGE(23, 31, 147-149, 151, 196).
Using a saturation dive model with direct ascent to the surface, Dromsky et al. found that
the administration of I.V. PFC while breathing 95% oxygen was able to decrease the
lethality of this decompression insult, decrease the incidence of DCS, and decrease the
number of neurological events(31). Similarly it has been found that I.V. PFC can improve
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outcomes after massive VGE, cerebral AGE, and coronary AGE(148-150). The
administration of I.V. PFC has also been shown to increase nitrogen washout through the
lungs after venous air embolism(196). Clearly PFC administration is of benefit in the
treatment of decompression illnesses, but the exact mechanism of this benefit has not yet
been elucidated. Is this benefit a result of the PFCs ability to increase nitrogen washout,
and thus, presumably, to remove the bubbles obstructing circulation faster? Is it a product
of improving the oxygen supply and thus metabolic state of tissue to which blood flow and
oxygen supply has been disturbed? Is it some combination of these two processes?
Helium-based breathing mixes also offer an interesting and relatively unexplored
avenue of investigation. It is well understood that helium-based breathing gases improve
ventilation and clinical condition in asthma and chronic obstructive pulmonary disease
(COPD) patients(44, 139, 143). This improvement is a product of the physical properties
of helium(43). Helium is approximately an order of magnitude less dense than either
oxygen or nitrogen and helium-oxygen (HeO2) mixtures are always less dense than
nitrogen-oxygen mixtures(43). Inhaling HeO2 mixtures alters ventilatory mechanics by
modifying gas convection in the airways thus increasing alveolar ventilation(28, 30, 43).
The dramatically decreased density of HeO2 mixtures compared to nitrogen-oxygen
mixtures results in airflow through conducting airways being much less turbulent(28, 30,
43, 124, 184). This laminar flow, in turn, results in less airway resistance and a much
smaller pressure gradient being required to move gas through the tracheo-bronchial
tree(28, 30, 43, 124, 184). Clinically this reduces the work of breathing and improves
oxygen delivery to the alveoli(28, 30, 43, 124, 184). These improvements have been
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observed not only in spontaneously breathing patients, but also in patients receiving both
non-invasive positive pressure ventilation and mechanical ventilation(42, 83, 84, 94).
The research described here was designed to investigate the effect of I.V. PFC
emulsions and helium-based breathing mixtures, both administered acutely after surfacing,
on nitrogen washout in an ovine model of severe DCS.

Materials and Methods
This study was performed in conjunction with the whole-body oxygenation study
described above in chapter 2.
All animal experiments performed for this project were done in strict accordance
with the National Institutes of Health (NIH) “Guide for the Care and Use of Laboratory
Animals” and were approved by both the Department of Defense (DoD) and the Virginia
Commonwealth University Institutional Animal Care and Use Committee (IACUC).
Juvenile Dorper cross sheep of either sex (Robinson Services, Inc., Mocksville, NC)
weighing 15-20 kg were housed in United States Department of Agriculture (USDA)- and
Association for Assessment and Accreditation of Laboratory Animal Care International
(AAALAC)-approved facilities in social flocks with free access to food and water on a 12hour light/dark cycle. Sheep were allowed a minimum of 3 days for acclimatization and
veterinary inspection prior to their use in any experiment.
Sheep Instrumentation and Preparation
48 hours prior to the experiment, sheep were muzzled to prevent access to food and
provide free access to water while remaining with the remainder of their flock in order to
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limit animal stress. Sheep were initially sedated with ketamine/xylazine (20.0/2.0 mg/kg
I.M.) and the animal was placed supine on the surgical table. All animals were promptly
intubated with a 9.0 mm internal diameter (I.D.) cuffed endotracheal tube (Hudson RCI,
Temecula, CA) and ventilated with 50/50 nitrogen/oxygen using a Siemens 900C servo
ventilator (Siemens Corp., New York, NY) set to a tidal volume of approximately 10
mL/kg adjusted to maintain arterial pCO2 at 40 mmHg ± 5 mmHg. An orogastric tube
fashioned from TYGON® R-3603 tubing (Satin-Gobain Performance Plastics Corp.,
Akron, OH) was advanced into the rumen to allow for fluid drainage and to allow gas
accumulated in the gut during the air dive to vent upon decompression. A MAC® 2-port
introducer sheath (Arrow International Inc., Reading, PA) was placed in the right external
jugular vein to allow for the administration of fluids and the anesthetic cocktail. Once I.V.
access was secured, administration of the triple drip anesthetic cocktail
(ketamine/xylazine/guaifenesin 2.0/0.1/50.0 mg/mL in 5% dextrose) was begun
immediately at 1.0-2.0 mL/kg/hr, titrated to maintain a surgical plane of anesthesia using a
Harvard Apparatus PHD 2000 programmable syringe pump (Harvard Apparatus,
Holliston, MA). The right femoral artery was canulated with an 18 gauge (G) femoral
arterial catheter (Arrow International Inc., Reading, PA) for monitoring of arterial pressure
(AP) and arterial blood sampling. The right femoral vein was canulated with a 4 French
(Fr) double lumen catheter (Arrow International Inc., Reading, PA) for the administration
of the anesthetic cocktail while inside the hyperbaric chamber and for the administration of
the treatment drug after exiting the hyperbaric chamber. The left femoral vein was
canulated for the placement of a 7.5 Fr CCOmbo® continuous cardiac output (CCO)
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pulmonary artery catheter to allow for CCO monitoring, central venous (CVP) and
pulmonary arterial pressure (PAP) monitoring, and central venous blood sampling.
Respiratory gases were continuously monitored using an MGA 1100 respiratory mass
spectrometer (Perkin-Elmer, Norwalk, CT). Following surgical manipulations all animals
were allowed to stabilize for a minimum of 30 minutes. After stabilization animals were
weaned off the ventilator until capable of spontaneously breathing prior to being placed
inside the hyperbaric chamber.
Inclusion/Exclusion Criteria
At the end of the stabilization period all animals were required to meet certain
inclusion criteria prior to being weaned off the ventilator and placed in the hyperbaric
chamber. The inclusion criteria were as follows: mean arterial pressure above 60 mmHg,
arterial pO2 above 200 mmHg, arterial pH 7.45 ± 5, arterial pCO2 40 ± 5 mmHg. All
animals not meeting the above inclusion criteria were excluded from the study and
euthanized.
Sheep Dry Dive Procedures
All sheep that met the study inclusion criteria (n=31) were weaned off the ventilator
until capable of breathing spontaneously, disconnected form all monitoring equipment and
placed into a Reimers Systems model #17-48-100 Research Hyperbaric Chamber (Reimers
Systems, Inc., Springfield, VA). During the dry dive procedures all animals breathed room
air and general anesthesia was maintained using a continuous infusion of triple drip as
described above. All sheep were subjected to the following dive profile: Beginning at 1.0
ATA the chamber was compressed at a rate of 1.0 ATA/minute to a pressure of 2.0 ATA.
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From 2.0 ATA the chamber was compressed at a rate of 2.0 ATA/min to a pressure of 6.0
ATA (165 feet of seawater (fsw), or 608 kilopascals (kPa)). The pressure of 6.0 ATA was
maintained for 27 minutes after which sheep were immediately decompressed to 1.0 ATA
at a rate of 2.0 ATA/minute.
Post-Decompression Monitoring
Upon complete decompression (considered time=0) all animals were quickly
removed from the hyperbaric chamber and all monitoring equipment was reconnected. At
this point animals were randomized to receive I.V. infusion of either 6.0 mL/kg Oxycyte®
PFC emulsion (n=15) (Synthetic Blood International, Costa Mesa, CA) or saline control
(n=16) and one of four breathing gases; 100% oxygen (n=8), 80/20% nitrogen/oxygen
(n=8), 50/50% helium/oxygen (n=7), or 80/20% helium oxygen (n=8). Animals were
randomized using a block randomization scheme such that for every 8 experiments
performed, one animal fell into each of the 8 treatment groups, but the order within each
block was random. Data from all instruments was recorded directly to hard drive storage
using the BioPac system and Acqknowledge v. 3.90 software (BioPac Systems, Inc.
Goleta, CA). Neuromuscular blockade with I.V. pancuronium (0.1 mg/kg) administered
acutely post-chamber was necessary in order to accurately measure respiratory gases with
the mass spectrometer.
Statistical Methods
Nitrogen washout curves for the 5 minute period beginning at time=0. Breath-bybreath measures of end-tidal nitrogen were plotted against time and analyzed using non-
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linear regression to fit a single exponential decay curve to the data using the following
equation:
y = α ( − Kx ) + β
Where α = peak
K = decay constant
β = plateau
This curve-fitting generates 3 variables which can be examined: First, a value for
the y-intercept, hereafter referred to as the ‘peak’. Second, a value for the exponential
decay constant, which represents the rapidity with which nitrogen is eliminated. Higher
numbers indicate more rapid elimination. Third, a value for the level which the right-most
portion of the curve asymptotically approaches, hereafter referred to as the ‘plateau’. This
number represents the extent to which nitrogen is eliminated with lower numbers
indicating greater elimination. Since this study was examining only nitrogen washout and
not initial body nitrogen loading, the peak was not analyzed. One-way ANOVA followed
by Dunnett’s test using the 100% oxygen-breathing group as the control group was
employed in order to examine differences between groups in the decay constant and
plateau. Student’s t-test was used in cases where only 2 groups were being compared. Data
are presented as Means ± Standard Error. Curve-fitting and statistical analyses were
performed using GraphPad Prism 4 curve-fitting and statistical software (GraphPad
Software, Inc. San Diego, CA).
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Results
Before plotting nitrogen washout curves as described above all 8 groups were
separated into 2 broad categories – those with nitrogen in their inhaled gas (Saline + Room
Air (n=4) and PFC + Room Air (n=4) groups) and those without nitrogen in their inhaled
gas (Saline + 100% O2 (n=4), Saline + 50/50 HeO2 (n=4), Saline + 80/20 HeO2 (n=4), PFC
+ 100% O2 (n=4), PFC + 50/50 HeO2 (n=3), and PFC + 80/20 HeO2 (n=4)). The 2 groups
with nitrogen in their inhaled gas were analyzed separately from the other 6 groups
because it is not possible for them to eliminate nitrogen to the extent the other groups can,
given that their inhaled gas contains 80% nitrogen.
Fitting of the end-tidal nitrogen data from the groups with nitrogen in their inhaled
gas (Saline + Room Air and PFC + Room Air) to the above single exponential decay
equation resulted in the curves seen in Figure 11. Details of the nonlinear fit are shown in
Table 7.
Table 7: Best-fit values resulting from the fit of a single exponential curve to the
end-tidal nitrogen data obtained from the Saline + Room Air and the PFC + Room Air
groups.

Best-fit Values
Decay Constant
Plateau
Standard Error
Decay Constant
Plateau
95% Confidence Interval
Decay Constant
Plateau

Saline + Room Air

PFC + Room Air

0.02453
566.3

0.02871
563.0

0.02017
1.136

0.008135
0.6879

-0.01501 to 0.06408
564.1 to 568.5

0.01277 to 0.04466
561.7 to 564.4
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When the decay constants obtained from the Saline + Room Air and PFC + Room
Air curve fittings were compared using Student’s t-test it was found that there was no
statistically significant difference (0.02453 ± 0.02017 vs. 0.02871 ± 0.008135 Saline vs.
PFC, t=0.1922, p=0.8539). See figure 12.
When the plateaus obtained from the Saline + Room Air and PFC + Room Air
curve fittings were compared using Student’s t-test it was found that the plateau for the
Saline + Room Air group was significantly higher than that for the PFC + Room Air group
(566.3 ± 1.136 vs. 563.0 ± 0.6879 mmHg, t=2.485, p=0.0475). See figure 13.
Fitting of the end-tidal nitrogen data from the groups without nitrogen in their
inhaled gas (Saline + 100% O2, Saline + 50/50 HeO2, Saline + 80/20 HeO2, PFC + 100%
O2, PFC + 50/50 HeO2, and PFC + 80/20 HeO2) to the above single exponential decay
equation resulted in the curves seen in figure 14. Details of the nonlinear fit are shown in
Table 8.
One-way ANOVA was used to compare the decay constants obtained from the
Saline + 100% O2, Saline + 50/50 HeO2, Saline + 80/20 HeO2, PFC + 100% O2, PFC +
50/50 HeO2, and PFC + 80/20 HeO2 groups. The ANOVA was found to be significant
(p<0.0001). Dunnett’s post-hoc test using the Saline + 100% O2 group as the control group
revealed that there were no statistically significant differences between the Saline + 100%
O2,group and the Saline + 80/20 HeO2, PFC + 100% O2, and PFC + 50/50 HeO2 groups
(0.03363 ± 0.001518 vs. 0.03067 ± 0.002362, 0.02758 ± 0.001444, and 0.02976 ±
0.002260, respectively). Dunnett’s post-hoc test also found that the decay constants for the
Saline + 50/50 HeO2 and the PFC + 80/20 HeO2 groups were significantly higher than that
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of the Saline + 100% O2 group (0.03363 ± 0.001518 vs. 0.04186 ± 0.001003, p<0.05; and
0.04481 ± 0.001343, p<0.01, respectively). See figure 15.
Table 8: Best-fit values resulting from the fit of a single exponential curve to the
end-tidal nitrogen data obtained from the Saline + 100% O2, Saline + 50/50 HeO2, Saline +
80/20 HeO2, PFC + 100% O2, PFC + 50/50 HeO2, and PFC + 80/20 HeO2 groups.

Best-fit
Values
Decay
Constant
Plateau
Standard
Error
Decay
Constant
Plateau
95%
Confidence
Interval
Decay
Constant
Plateau

Saline +
100% O2

Saline +
50/50
HeO2

Saline +
80/20
HeO2

PFC +
100% O2

PFC +
50/50
HeO2

PFC +
80/20
HeO2

0.03363

0.04186

0.03067

0.02758

0.02976

0.04481

26.17

23.40

21.22

16.82

15.88

17.00

0.001518

0.001003

0.002362

0.001444

0.002260

0.001343

2.425

1.189

2.903

2.621

2.996

1.177

0.03066
to
0.03661
21.41
to
30.92

0.03989
to
0.04382
21.07
to
25.73

0.02604
to
0.03530
15.53
to
26.91

0.02475
to
0.03041
11.68
to
21.95

0.02533
to
0.03419
10.01
to
21.76

0.04218
to
0.04744
14.69
to
19.30

When the plateaus obtained from the Saline + 100% O2, Saline + 50/50 HeO2,
Saline + 80/20 HeO2, PFC + 100% O2, PFC + 50/50 HeO2, and PFC + 80/20 HeO2 curve
fittings were compared to the Saline + 100% O2 group using one-way ANOVA it was
found that the whole model was significant (p=0.0294). Dunnett’s post-hoc test revealed
that there was no statistically significant difference between the Saline + 100% O2 group
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and the Saline + 50/50 HeO2 and Saline + 80/20 HeO2 groups (26.17 ± 2.425 vs. 23.40 ±
1.189 and 21.22 ± 2.903, respectively). Dunnett’s post-hoc test also revealed that the
plateaus for the PFC + 100% O2, PFC + 50/50 HeO2, and PFC + 80/20 HeO2 groups were
significantly lower than that of the Saline + 100% O2 group (26.17 ± 2.425 vs. 16.82 ±
2.621, p<0.05; 15.88 ± 2.996, p<0.05; and 17.00 ± 1.177, p<0.05, respectively). See figure
16.
In order to better examine the specific effects of the PFC and the various breathing
gas mixes independently, the data were pooled based on PFC (n=11) vs. saline (n=12)
administration as well as by breathing gas administered (100% O2 (n=8), 50/50 HeO2
(n=7), or 80/20 HeO2 (n=8)).
Fitting of the end-tidal nitrogen data from the pooled saline- and PFC-treated
groups to the above single exponential decay equation resulted in the curves seen in figure
17. Details of the nonlinear fit are shown in Table 9.
Table 9: Best-fit values resulting from the fit of a single exponential curve to the
end-tidal nitrogen data obtained from the saline- and the PFC-treated groups.

Best-fit Values
Decay Constant
Plateau
Standard Error
Decay Constant
Plateau
95% Confidence Interval
Decay Constant
Plateau

Saline

PFC

0.03176
22.22

0.03096
15.98

0.001044
1.566

0.0009402
1.380

0.02971 to 0.03380
19.15 to 25.29

0.02912 to 0.03280
13.28 to 18.69
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When the decay constants obtained from the saline- and PFC -treated curve fittings
were compared using Student’s t-test it was found that there was no statistically significant
difference (0.03176 ± 0.001044 vs. 0.03096 ± 0.0009402 saline vs. PFC, t=0.5656,
p=0.5777). See figure 18.
When the plateaus obtained from the saline- and PFC-treated curve fittings were
compared using Student’s t-test it was found that the plateau for the saline-treated group
was significantly higher than that for the PFC-treated group (22.22 ± 1.566 vs. 15.98 ±
1.380 mmHg, t=2.967, p= 0.0074). See figure 19.
Fitting of the end-tidal nitrogen data from the pooled breathing gas groups to the
above single exponential decay equation resulted in the curves seen in figure 20. Details of
the nonlinear fit are shown in Table 10.
Table 10: Best-fit values resulting from the fit of a single exponential curve to the
end-tidal nitrogen data obtained from the 100% O2-, 50/50 HeO2-, and 80/20 HeO2breathing groups.
100 % O2
Best-fit Values
Decay Constant
0.02649
Plateau
19.14
Standard Error
Decay Constant
0.001056
Plateau
2.154
95% Confidence
Interval
Decay Constant 0.02442 to 0.02856
Plateau
14.91 to 23.36

50/50 HeO2

80/20 HeO2

0.02826
16.29

0.03786
19.80

0.001326
2.175

0.001518
1.548

0.02566 to 0.03086
12.03 to 20.55

0.03488 to 0.04084
16.76 to 22.83

When the decay constants obtained from the 50/50 HeO2 and 80/20 HeO2 curve
fittings were compared to the 100% O2 group using one-way ANOVA followed by
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Dunnett’s post-hoc test it was found that the ANOVA was significant (p<0.0001).
Dunnett’s post-hoc test showed that there was no statistically significant difference
between the 100% O2 group and the 50/50 HeO2 group (0.02649 ± 0.001056 vs. 0.02826 ±
0.001326, p>0.05). It was also found that the decay constant for the 80/20 HeO2 group was
significantly higher than that of the 100% O2 group (0.03786 ± 0.001518 vs. 0.03363 ±
0.001518, p<0.01). See figure 21.
When the plateaus obtained from the 50/50 HeO2 and 80/20 HeO2 curve fittings
were compared to the 100% O2 group using one-way ANOVA it was found that the
ANOVA was not statistically significant (p=0.4381). See figure 22.
Discussion and Conclusions
As is intuitively obvious, the data gathered from the air-breathing animals
demonstrates clearly that a low fraction of inspired nitrogen (FIN2) is required for effective
nitrogen washout to take place. This should come as no surprise. Nitrogen washout, like
any other process of diffusion, relies on a concentration gradient. So long as there is a high
level of nitrogen in the alveolar gas there is little driving force to remove nitrogen from the
blood. At the same time, the degree to which nitrogen can be removed is severely limited.
Diffusion of nitrogen out of the blood into the alveolar gas will only proceed until the
concentration of nitrogen is balanced across the alveolar wall. Because of this limit
imposed on off-gassing, it makes no sense to compare the groups breathing room air with
the other groups breathing 100% oxygen or heliox mixtures, the latter of which all have
FIO2 of zero.
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There were two major findings that came out of this project. Firstly, the
administration of HeO2 results in higher decay constant values without affecting plateau
values. Secondly, the administration of PFC results in lower plateau values without
affecting decay constant values. The decay constant is a measure of how quickly the endtidal nitrogen is changing, or practically speaking, how quickly the nitrogen is being
removed. Higher values indicate that the end-tidal nitrogen is decreasing faster, i.e.
nitrogen washout is proceeding more quickly.
When the 6 treatment groups are analyzed separately it is interesting to see that the
effects of helium were not dose dependant and would appear to be dependant on the
intravenous therapy administered. When I.V. saline was administered, 50/50 HeO2 resulted
in a significant increase in the decay constant, while 80/20 HeO2 showed no difference vs.
100% O2. When I.V. PFC was administered the opposite was true - 80/20 HeO2 resulted in
a significant increase in the decay constant, while 50/50 HeO2 showed no difference vs.
100% O2. What this represents is unclear. It may represent a difference in the number and
size of bubbles lodged in the pulmonary microcirculation which is unrelated to either PFC
administration or breathing gas, but rather represents a manifestation of the stochastic
nature of DCS and the relatively small group sizes. In this case examining the data pooled
based on breathing gas is likely to be much more informative.
This pooled data indicated that the decay constant in the 80/20 HeO2 group was
significantly higher than the 100% O2 group, but that the 50/50 HeO2 group was not
different. This suggests that a high FIHe is required to have maximum impact on increasing
the speed of nitrogen washout. This is not surprising. Since the benefits of helium lie
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purely in its physical properties, primarily its density, these benefits will be lost as the FIHe
decreases. HeO2 has been administered previously for the treatment of experimental
DCS(3, 78-81). These studies have shown that breathing HeO2 is of benefit both when
used during recompression and at 1 atmosphere absolute (ATA) after decompression(3,
78-81). However, there is no record in the scientific literature of previous investigations
examining the effect of HeO2 on nitrogen washout. Previous studies have examined either
death rates or used microscopic observation of the growth and shrinkage of bubbles
deliberately placed in surgically exposed tissue (primarily adipose tissue)(3, 78-81). This
study, therefore, represents the first examination of the mechanism of the previouslydescribed benefits of HeO2 breathing after DCS.
The effect of PFC administration was very different from that of helium. PFC
resulted in a decrease in the plateau without affecting the decay constant. The plateau
represents the level to which end-tidal nitrogen is decreased over the period of observation,
and thus the extent to which nitrogen is removed. Lower values for the plateau indicate that
more nitrogen has been removed. It was found that the administration of PFC resulted in
lower plateau values across the board. This was observed amongst all the different
breathing gases, including the room air groups – all the PFC-treated groups showed
significantly lower plateau levels than the saline-treated groups. This indicates that PFC
administration, while not affecting the speed of nitrogen washout, results in nitrogen
washout proceeding to a greater extent. Only two previous studies have examined the
effect of PFC administration on nitrogen washout and the findings of this study agree well
with both of them(99, 196). Both of these previous studies were conducted at 1 ATA,
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Lundgren et al. using a model where nothing was done to increase the amount of nitrogen
dissolved in body tissues and Zhu et al. using a venous gas embolism model(99, 196). The
present study represents the first demonstration that the ability of PFC to enhance nitrogen
washout is retained in the DCS situation where blood flow through the pulmonary
microcirculation is disrupted by the presence of large numbers of bubbles.
The findings of the current study offer insight into the mechanism for the
previously observed protective effects of both HeO2 breathing and I.V. PFC administration
in treating DCS. This study demonstrates for the first time that the effect of HeO2 is to
increase the speed of nitrogen washout. This study also demonstrates for the first time that
the effect of the PFC is to increase the amount of nitrogen washed out. Although we were
able to demonstrate statistically significant effects of I.V. PFC, these results must be taken
with a grain of salt since the magnitude of this effect was so small that it is likely it is of
little or no clinical relevance. Up until this point it has been widely believed that the
therapeutic benefit derived from the administration of PFC in cases of severe DCS were
largely a product of their ability to dissolve inert gases such as N2, and aid in the removal
of excess N2 from the body, thus alleviating the bubble obstructions and restoring normal
tissue blood flow(23, 31, 98, 100, 102, 151, 175). This work has demonstrated that,
although PFC administration does, indeed, increase nitrogen washout, that this effect is so
small, a mere 6.24 mmHg difference, that it is not very likely that this explaines the
dramatic protective effects previously observed with the administration of I.V. PFC after
decompression(23, 31, 100, 102, 151, 175). This novel finding combined with the results
from study 1 described above shed new light on the likely mechanism of the protection
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afforded by PFC administration after DCS. These findings suggest strongly that improved
tissue oxygenation is far more important than minimal increases in nitrogen washout.
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Figure 11: Nitrogen washout curves from the groups with nitrogen in their inspired
gas.
Best-fit curves resulting from the fit of a single exponential curve to the end-tidal
nitrogen data obtained from the Saline + Room Air and the PFC + Room Air groups. For
Saline + Room Air R2=0.02240, for PFC + Room Air R2=0.1210.
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Figure 12: Comparison of the decay constants from the groups with nitrogen in
their inspired gas.
The decay constants from the groups with nitrogen in their inhaled gas were
compared using Student’s t-test. It was found that there was no significant difference
between the Saline + Room Air group and the PFC + Room Air groups.
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Figure 13: Comparison of the plateaus from the groups with nitrogen in their
inspired gas.
The plateaus from the groups with nitrogen in their inhaled gas were compared
using Student’s t-test. It was found that the plateau for the PFC + Room Air group was
significantly lower than that of the Saline + Room Air group.
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Figure 14: Nitrogen washout curves from the groups without nitrogen in their
inspired gas.
Best-fit curves resulting from the fit of a single exponential curve to the end-tidal
nitrogen data obtained from the Saline + 100% O2 (R2= 0.8691), Saline + 50/50 HeO2 (R2=
0.9614), Saline + 80/20 HeO2 (R2= 0.7483), PFC + 100% O2 (R2= 0.8300), PFC + 50/50
HeO2 (R2= 0.7516), and PFC + 80/20 HeO2 (R2= 0.9387) groups.
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Figure 15: Comparison of the decay constants from the groups without nitrogen in
their inspired gas.
The decay constants from the groups without nitrogen in their inhaled gas were
compared to the decay constant of the Saline + 100% O2 group using one-way ANOVA
followed by Dunnett’s test. It was found that decay constants for both the Saline + 50/50
HeO2 and the PFC + 80/20 HeO2 groups were significantly higher than that of the Saline +
100% O2 group.
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Figure 16: Comparison of the plateaus from the groups without nitrogen in their
inspired gas.
The plateaus from the groups without nitrogen in their inhaled gas were compared
to the plateau of the Saline + 100% O2 group using one-way ANOVA followed by
Dunnett’s test. It was found that the plateaus for the PFC + 100% O2, PFC + 50/50 HeO2
and PFC + 80/20 HeO2 groups were all significantly lower than that of the Saline + 100%
O2 group.
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Figure 17: Nitrogen washout curves from groups pooled based on PFC
administration.
Best-fit curves resulting from the fit of a single exponential curve to the end-tidal
nitrogen data obtained from the pooled saline- and the PFC-treated groups. For saline
R2=0.8201, for PFC R2= 0.8249.
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Figure 18: Comparison of the decay constants from the pooled saline- and PFCtreated groups.
The decay constants from the saline- and PFC-treated groups were compared using
Student’s t-test. It was found that there was no significant difference between the salinegroup and the PFC-treated groups.
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Figure 19: Comparison of the plateaus from the pooled saline- and PFC-treated
groups
The plateaus from the saline- and PFC-treated groups were compared using
Student’s t-test. It was found that the plateau for the PFC-treated group was significantly
lower than that of the saline-treated group.
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Figure 20: Nitrogen washout curves from groups pooled based on breathing gas
administration.
Best-fit curves resulting from the fit of a single exponential curve to the end-tidal
nitrogen data obtained from the pooled 100% O2 (R2= 0.8046), 50/50 HeO2 (R2= 0.7805),
and 80/20 HeO2 (R2= 0.8198) breathing gas groups.
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Figure 21: Comparison of the decay constants from the pooled breathing gas
groups
The decay constants from the 50/50 HeO2 and 80/20 HeO2 breathing groups were
compared to the decay constant of the 100% O2 group using one-way ANOVA followed
by Dunnett’s test. It was found that the decay constant for the 80/20 HeO2 group was
significantly higher than that of the 100% O2 group.
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Figure 22: Comparison of the plateaus from the pooled breathing gas groups
The plateaus from the 50/50 HeO2 and 80/20 HeO2 breathing groups were
compared to the decay constant of the 100% O2 group using one-way ANOVA followed
by Dunnett’s test. It was found that there were no significant differences between the
groups.

CHAPTER 4

GENERAL DISCUSSION AND CONCLUSIONS
The problem of DCS is unlikely to pass quietly into the night. In fact, it is more
likely that the incidence of DCS will increase in the coming years. Although DCS is better
understood now than it has ever been, the simple fact that it is largely a stochastic
phenomenon all but guarantees that it will never go away. The probabilistic nature of DCS
also means that its incidence is likely to increase as the number of people involved in
diving increases. Current estimates place the number of recreational dives performed
worldwide per year above 3 million, and the incidence of DCS somewhere between 0.1
and 9.8 cases of DCS per 100 divers, or between 1.0 and 28.1 cases of DCS per 10,000
dives(25, 167). Diving is also a sport which is increasing in popularity. A five-fold
increase in the number of people participating in recreational diving was observed between
in the 15 year period between 1985 and 2000(161).
The incidence of DCS in recreational diving alone would be sufficient to indicate
that DCS will continue to be a problem for the foreseeable future, but recreational diving is
not the only source of DCS. DCS is also encountered in the much more controlled realms
of commercial and military diving. Although numbers are much harder to come by, DCS
incidence in the commercial diving industry is believed to be between 1 case in 800 to
4000 dives, depending largely on the decompression tables being used(8). The military has
fundamentally different objectives with its diving programs compared to either recreational
94
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diving or commercial diving. Due to the nature of the work, a certain risk, and thus
incidence of DCS, is considered ‘acceptable’ within the realm of military diving.
Decompression table development for the US Navy is currently undertaken with the
understanding that the acceptable incidence of DCS is 2.2%(163). The actual incidence of
DCS within the realm of military diving is believe to be between 2 and 5 %, again,
depending largely on which decompression tables are being used(163). Both commercial
and military diving activities are unlikely to diminish in the short term, so even in these
communities DCS is likely to be an ongoing problem for the foreseeable future. DCS also
continues to be a problem in space exploration. When astronauts are operating outside the
space vehicle their suits must be pressurized to approximately 0.25 ATA in order to allow
them to operate the joints(168). Given that the crew spaces of both the space shuttles and
International Space Station are pressurized to approximately 1.0 ATA with a gas miture
much like room air, great time and care must be taken to denitrify astronauts prior to
extravehicular activity in order to reduce the risk of decompression sickenss(68, 168).
Previous studies exploring the use of PFCs to treat and prevent DCS have
demonstrated that the I.V. administration of PFC emulsions after decompression decreases
morbidity and mortality in both a clear and consistent fashion(23, 31, 147-149, 151, 196).
This prior work has all been done in conscious, spontaneously breathing, freely moving
animals. This laboratory is the only laboratory conducting DCS research in anaesthetized,
instrumented animal models. As such we are uniquely equipped to examine not only the
survival benefits of PFC administration, but to elucidate the mechanism by which these
benefits are provided. The studies described in this dissertation were the first studies
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purposed to examine two potential mechanisms by which PFCs exert their protective
effects – namely that they improve oxygenation and that they improve nitrogen (or any
other inert gas) washout.
Study 1 in Chapter 2 above demonstrated that PFC administration improved wholebody oxygenation. Although it is rather intuitive that the administration of a therapy which
is known to dissolve greater quantities of oxygen than blood plasma , such as PFC, should
increase arterial oxygen content, this is the first study to demonstrate that this is, in fact,
 and DO
 demonstrates that this
the case in vivo. That PFC is also able to increase both VO
2
2

increased oxygen carrying capacity granted by PFC administration has functional benefits
as well. Thus it is likely that at least a portion of the benefits previously observed with PFC
administration are directly attributable to improved tissue oxygenation. Unfortunately this
study was only able to make these measures at the whole-body level. Moving forward it
 and VO

would be important to examine the effects of PFC administration on CaO2 , DO
2
2

in specific tissues, ideally in areas where blood flow is known to be obstructed by bubbles.
Furthermore, in order to examine the mechanism by which PFC improves tissue
oxygenation, it would be beneficial if some means to track the location of the PFC
emulsion particles could be devised. While labeling the PFC itself is difficult due to their
non-reactivity it might be possible to label the emulsifiers, and thus track the location of
the emulsion particles. These studies could be used to determine if the PFC particles are
able to flow past bubble obstructions, or perhaps move through them. Similarly, in order to
examine how PFC improves oxygen delivery to cells and cellular organelles, labeled PFC
emulsion particles could be used to determine if the PFC extravasates or remains within
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the circulatory system. Much work remains to be done in order to fully understand exactly
how PFC improves oxygenation.
Study 2 in Chapter 3 above demonstrated that PFC is able to increase the degree to
which nitrogen is removed, but not the speed with which it is removed. This same study
also demonstrated that high FIHe was able to increase the speed with which nitrogen was
removed, but not the degree to which it was removed. If nitrogen washout is to be studied
in the future it would be desirable to carry such studies over longer periods of time, and to
use other techniques in addition to real-time respiratory mass spectrometry to examine
exhaled nitrogen. If exhaled gases were collected in a bag and the contents of the bag
examined at various time points, data could be gathered with respect to not only the
instantaneous partial pressure of nitrogen in the gas, but also the volume of gas expired.
The above conclusions from Study 2 suggest a potential beneficial effect of
combining both PFC and high FIHe for increasing the amount and rapidity of nitrogen
washout. This study was, however, neither powered, nor designed to elucidate differences
seen due to the combined effects of PFC administration and high FIHe. As such this
investigator does not believe that such effects would be substantive.
The beneficial effects of helium were only observed when the inspired breathing
mix was 80% helium. With only 20% of the inspired gas consisting of oxygen it is unlikely
that the oxygenation benefits of the PFC would be retained. This investigator also
questions the wisdom of administering breathing mixes containing high FIHe after
decompression. Although the research done to date suggests that HeO2 breathing with a
high FIHe after decompression results in faster bubble shrinkage and disappearance, the
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results of these studies are of questionable relevance to clinical DCS(3, 10, 78-81). First,
these studies were all conducted in rats, and it is well understood that rats do not develop
DCS in the same way that humans and larger mammals do(39, 97). Their small body mass
appears to offer a protective effect and more severe dive profiles are required to reliably
generate DCS in rats than is required for larger mammals. Additionally these studies were
not studying DCS per se, but rather were examining the growth, shrinkage, and
disappearance of bubbles deliberately injected into adipose tissue prior to a hyperbaric
exposure. The dive profile itself was not severe enough to result in de novo bubble
formation(3, 10, 78-81). Although very interesting, this is a very different phenomenon
from clinical DCS. It is unlikely that tissue gas tensions are as high in these models as they
would be in clinical DCS. As such the growth and shrinkage of bubbles could not be
expected to follow a similar time course in these models as would be the case in DCS.
Even if we were to interpret these results as representative of the growth and
shrinkage of bubbles in circulation, the fastest shrinking bubbles required nearly 70
minutes to disappear(79-81). Although the removal of bubbles obstructing circulation and
restoration of normal blood flow are important factors in tissue injury, the reason blood
flow restoration is important is to restore oxygen delivery. It seems foolish to this
investigator to hamper the ability of PFC to deliver oxygen to tissue by decreasing the FIO2
in order to decrease bubble dwell time from several hours to over 1 hour. It would appear
to be of greater benefit to restore some oxygen delivery to tissue, even if it isn’t a complete
return to baseline, by administering PFC in combination with 100% oxygen breathing.
This scenario seems more likely to maximize tissue survival in the case of DCS.
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In future work studying the use of PFC for treating DCS, great care should be
exercised in model choice. Previous work examining PFC administration to swine
demonstrated clearly that pigs develop a pulmonary hypertensive response to PFC which is
severe enough to result in decreased cardiac output(152). Findings from study 1 above
demonstrate that a similar, though less severe, response occur in sheep as well. It is likely
that this response will be observed in all cloven-hoofed animals. In order to get the clearest
possible picture of how PFC effects oxygenation, it would be desirable to utilize a species
in which this response does not occur.
Other issues in model selection include the use of conscious vs. anaesthetized
animals, as well as spontaneously breathing vs. ventilated animals. These issues become
important in the development and evolution of DCS. As discussed in the introduction
above, one likely mechanism for the formation of bubbles during the development of DCS
is cavitation nucleation. This occurs as a result of motion. Therefore the question of
whether to use conscious vs. anaesthetized animals arises. Anaesthetized animals do not
move spontaneously, and any movement imposed externally by investigators will not
duplicate the normal muscle and joint movement as it would occur in a conscious, freemoving animals. Similarly, a spontaneously breathing animal is able to regulate its
ventilatory drive in response to stimuli such as changing arterial pCO2. A ventilatordependant animal will not be able to alter its ventilatory pattern in response to such stimuli.
As with all model choices, no one scenario is universally a better choice. Although a
conscious, spontaneously breathing, free moving animal might be ideal for examining
variables such as time to onset of symptoms, or mortality, it is very difficult to use such
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models for the invasive monitoring of physiological parameters such as cardiac output.
Models must be selected based on experimental objectives.
This work has demonstrated for the first time that the mechanism by which PFC
exerts its protective effects includes both improved oxygenation and increased nitrogen
removal. It is likely that the observed effects on oxygenation are more important in terms
of explaining the previously observed beneficial effects of PFC in treating DCS than are
the effects on nitrogen washout. Arterial oxygen content was increased 11% over saline


control, while DO
2 was increased by 10% and VO2 was increased by 22%. These are

substantial increases in oxygenation. Meanwhile when the nitrogen washout curves were
examined it was found that the plateau value for the PFC-treated group was 28% lower
when compared to the saline control group. Although this seems like a large relative
difference, in absolute terms the difference is only 6.24 mmHg.
Over the course of a long period of time this small difference may account for a
substantial difference in the total volume of nitrogen washed out. It is also likely that the
time required for the dissolution of bubbles is not decreased to a level which would
eliminate the interruption of blood flow and resultant hypoxia induced by bubbles lodging
in the circulation. The direct effect of PFC administration on the time required for bubble
dissolution has never been studied, but the effects of other therapies such as HeO2
breathing have been studied, as mentioned above. These studies indicated that when
breathing air, the worst possible breathing gas to treat DCS, bubbles persisted longer than
220 minutes(79-81). The exact time is unknown because bubbles persisted beyond the
period of observation. While breathing oxygen, the current gold-standard of DCS therapy,
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bubbles persisted for approximately 150 minutes on average(79-81). Breathing 50/50
HeO2, the gas which resulted in the shortest time required for bubble dissolution, reduced
bubble persistence to approximately 100 minutes on average(79-81). Even if we were to
suppose that the PFC is able to decrease bubble persistence by 100% over 50/50 HeO2,
bubble persistence times would still average 50 minutes. Obstructing circulation for 50
minutes is more than long enough to cause permanent injury in sensitive tissues such as
neural tissue where it is generally accepted that interruption of blood flow for intervals
greater than 6-10 minutes will result in permanent injury.
In conclusion, previous work has demonstrated clearly that PFC decreases DCS
morbidity and mortality. The work described in this dissertation demonstrated that the
most likely mechanism for the observed benefits is that PFC improves capacity of the
circulatory system to carry and deliver oxygen to tissue, as well as increasing the ability of
tissue to take up and use that oxygen. Although PFC does improve nitrogen washout, this
is likely a minor contributor to its previously-observed efficacy in the treatment of DCS. I
believe it is likely that PFC administration will one day become an adjunctive therapy in
the treatment of DCS and perhaps even a definitive therapy in mild-to-moderate cases.
This will require not only further animal study to demonstrate efficacy in less severe
models of DCS, but also extensive human testing in order to demonstrate a lack of toxicity,
appropriate dosing for humans, and will likely also require the development of new
recompression tables for use in patients who still require recompression after PFC
administration.
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Introduction
Gas anaesthesia is arguable one of the most important medical advances of the
last 200 years. Introduced to the Americas some 160 years ago, these drugs form the
foundation that all modern surgery is based on. Without surgical anaesthesia to render
patients immobile, insensitive to pain, and to abolish, or at least limit their memories of
the surgical experience, modern surgery would not be possible. Inhaled anaesthetics are
also among the most dangerous and poorly understood drugs available in the modern
arsenal – so much so that an entire specialty of medical practice has been developed in
order to ensure that those using these drugs have the proper training and experience to do
so safely. While gas anaesthesia has been a great boon for medicine, inert gas narcosis
has been the scourge of deep sea diving. Inert gas narcosis has placed some fairly strict
limits on the depths to which deep sea diving can be conducted safely, greatly limiting
our ability to explore the 70% of our planet covered by water, except through indirect
means such as the use of submersibles. In fact, it has been remarked that we know more
about the surface of Mars than we do about the deep ocean. These two topics of
discussion seem so far removed from one another that they have never really been
explored in tandem, but what if they are not really separate topics after all? What if gas
anaesthesia and inert gas narcosis are, in reality, different manifestations of the same
phenomenon?
History
The phenomenon now known as nitrogen narcosis, or more broadly as inert gas
narcosis, is a prime example of pharmacological activity of a so-called inert gas. From as
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early as 1835 (19, 65, 75), it was understood that hyperbaric exposure resulted in
symptoms such as sleepiness, impaired judgement, and hallucinations resembling
intoxication or drunkenness (19, 55, 75). Over the years a succession of explanations for
these observations has been postulated, including direct effects of pressure (19, 55, 75),
high partial pressures of oxygen (19, 35, 75), underlying psychological factors such as
latent claustrophobia (19, 63, 75), impurities in the breathing gas (19, 63, 75), and carbon
dioxide. None of these proposed mechanisms were ultimately able to explain the
mechanism of the observed symptoms without breaking down at some point. After a
century of investigation into the mechanism of what came to be know as ‘compressed air
narcosis’, in 1935 Behnke et al. first proposed what is now the commonly held theory
that the raised partial pressure of nitrogen was responsible for the observed symptoms
(13, 19). For several years there was a major rift in the emerging hyperbaric community
between the proponents of the nitrogen hypothesis and the carbon dioxide hypothesis (11,
12, 19, 75). However, work in the early 1970’s by Hesser et al. reconciled the nitrogen
and CO2 theories by demonstrating that the effects of nitrogen were the primary cause of
narcosis, but CO2 also had an additive effect on narcosis (19, 61, 62, 75).
Modern hypotheses
Inert Gas Theory
When Behnke et al. first proposed the currently held theory that the nitrogen (or
more broadly, the inert gas) fraction of the breathing gas is primarily responsible for
narcosis (13) in 1935, their assertion was based on what has come to be known as the
Meyer-Overton hypothesis, which, in brief, states that the narcotic potency of an
anaesthetic (or an inert gas) is related to its lipid solubility (78, 88). Lipid solubility is the
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one physical property of inert gases that has been found to correlate consistently with
their narcotic potency (19, 75). The Meyer-Overton hypothesis, with regards to inert gas
narcosis, was found to be tenable by Carpenter. He showed that at their isonarcotic partial
pressures, that is, the partial pressure at which each gas shows comparable pharmacologic
effects, the inert gas concentration dissolved in the lipid phase is very similar across
many gasses, but the partial pressure of gas required varies from 0.045 to 165 ATA (19,
29). Figure 1 also illustrates that lipid solubility correlates with relative narcotic potency
better than other physical properties (75).
This assumes that the mechanism of action for the narcotic effect of inert gases is
some sort of interaction with the lipid component of the central nervous system, which is
currently one of the plausible sites of action for anaesthetics. This has not always been
the case. The aqueous phase has also been suggested as a possible alternative (82, 89).
The first aqueous phase hypothesis is based on the formation of hydrates (19). Pauling
theorized that clathrates were formed in the aqueous phase such that the inert gas atoms,
which he called ‘guests’, are held by Van der Waals forces in crystalline cages formed by
the ‘hosts’, or molecules from within the cell, namely water molecules (89).
Unfortunately these hydrates would be unstable under body conditions, so Pauling was
forced to assume that there was some stabilizing factor present, such as the charged sidechains of proteins to make his theory workable (19, 89). Under this hypothesis the
clathrates caused narcosis by increasing the impedance of nerve tissue, trapping ions
involved in nerve conduction, and decreasing metabolism (19, 89). Miller proposed
another aqueous-phase model which, although related, did not rely on hydrates (19, 82).
Instead, Miller suggested that the presence of gaseous anaesthetics, such as inert gases,
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resulted in an increase in the size of highly ordered shells of water molecules surrounding
the dissolved gas molecule (19, 82). These ‘icebergs’ would decrease conductance in
brain tissue, stiffen lipid membranes, and occlude ion channels (19, 82). In the mid-tolate 1960’s work was done to settle the lipid phase vs. aqueous phase debate. This work
demonstrated clearly that lipid solubility was a far better indicator of narcotic potency
than hydrate dissociation pressure (43, 79, 80). No evidence was found in these studies to
support the idea that the aqueous phase was the critical phase for the action of anaesthetic
gasses.
Mechanisms
Once it was established that the site of action was, indeed, within the lipid phase
rather than the aqueous phase, hypotheses began to emerge regarding what was actually
taking place within the lipid phase that would result in narcosis with identical signs and
symptoms being induced by a broad collection of gasses with no common structural
features (75). Many hypotheses have evolved to explain the mechanism of inert gas
narcosis and anesthesia, including hypoxia, depression of metabolism, cell membrane
stabilization and stiffening causing decreased ion permeability, inhibition of the sodium
extrusion pump, increased production of inhibitory neurotransmitters such as gamma
aminobutyric acid (GABA) and interference with adenosine triphosphate (ATP)
production (15, 25, 44, 70, 84, 91, 93). These fall into two broad categories, biochemical
hypotheses or biophysical hypotheses. Biochemical theories imply some effect on
respiratory enzyme systems, while biophysical theories imply some interaction with, or
within part of the cell, such as the cell membrane (45, 59, 84, 101, 115). Until recently,
no good evidence had been found to support biochemical changes at pressures relevant to
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the clinical manifestations of inert gas narcosis (27, 28, 71, 74, 103, 111). This suggested
that the narcotic action is more likely biophysical than biochemical and evolved into the
‘unitary hypothesis of narcosis’ – that the mechanism of narcosis is the same for all
anaesthetic gasses (75).
By the late 1950’s, the site of action of narcotic gasses had been attributed to
synapses in the central nervous system. This was deduced largely from the work of
Carpenter in the mid 1950’s. He demonstrated that extremely high pressures (310-340
ATA) of argon, a gas with a narcotic potency more than twice that of nitrogen, were
required to effect a block of conduction in isolated peripheral nerve preparations. Yet
argon at a mere 18 ATA of pressure was sufficient to abolish any response to electrical
stimulus applied to the foot pad of mice (29, 30). This suggests strongly that higher level
functions in the brain are much more susceptible to inert gas narcosis than peripheral
nerves. Later work examining reflex inhibition in the spinal cord demonstrated that
inhibitory synaptic mechanisms were affected by inert gas narcosis before excitatory
mechanisms (14, 15, 31), and that inert gas narcosis, like general anaesthetics, affects
cells in the anterior horn of the spinal cord (7, 108, 109).
Lipid/Membrane Hypotheses
Physical hypotheses, based on the polarizability and the volume of inert gas
molecules are generally much simpler and, according to some, seem more likely than
biochemical hypotheses (19, 84). The critical volume hypothesis of general anaesthesia
proposed that narcosis occurred when the anaesthetic agent entered the lipid part of the
cell in sufficient quantity to cause the lipid portion of the cell, in particular the plasma
membrane, to swell (72, 81). Accordingly, changes in lipid volume ought to differentiate

125
the anaesthetized from the unanaesthetized state. The critical volume hypothesis is
supported by observations that anaesthetics and inert gases at increased ambient pressures
expand the volume of lipid monolayers and bilayers, bulk phase solvents, oils, and even
rubber (105). This hypothesis is further supported by the observation that gas anaesthesia
can be reversed with the application of hydrostatic pressure, see figure 2 (72, 81, 99). The
quantitative aspect of this hypothesis was developed which suggested that a 0.4%
expansion of the membrane would be required to produce anaesthesia (73).
Although elegant in its simplicity, there are critical elements of this hypothesis
that do not agree with observations. The critical volume hypothesis predicts that the
percentage change in anaesthetic potency ought to be linearly related to pressure, and that
the slope of this relationship ought to be the same for all anaesthetic agents (59). This has
not been found to be true. It has been demonstrated that there is not a universal linear
relationship between pressure and the anaesthetic dose required to maintain the same
level of anaesthesia (59, 67, 107, 116). Quite the opposite, it has been shown that these
pressure-anaesthetic interactions are curvilinear, and differ depending on the anaesthetic
in question (59, 67, 107, 116). For instance, the amount of nitrogen required to maintain a
given level of anaesthesia increases with pressure to ~50 ATA, at which point it plateaus
and there is no further increase for pressures up to ~130 ATA (59, 67, 107, 116).
Requirements for isoflurane, on the other hand, decrease up to pressures of ~8 ATA, after
which they increase sharply, and continue to increase up to pressures of ~100 ATA (59,
67, 107, 116). Additionally, it has been observed that there is no appreciable increase in
membrane thickness at narcotic concentrations of various agents (52, 106).
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These observations led to the postulation of the multi-site expansion hypothesis
(59). There are 5 key elements of this hypothesis (19, 59):
•

General anaesthesia or narcosis can be produced by the expansion of more
than one molecular site and these sites may have different physical
properties.

•

The physical properties of a molecular site may themselves be influenced
by the presence of anaesthetics or pressure (i.e. compressibility)

•

The molecular sites do not behave as if they were bulk solvents but have a
finite size and a finite degree of occupancy

•

Pressure need not necessarily act at the same site as the anaesthetic in
order to reverse anaesthesia. Depending on the anaesthetic, one of the sites
may predominate in determining the interaction between anaesthesia and
pressure

•

The molecular sites for anaesthesia are not perturbed by a decrease in
temperature in a manner analogous to an increase in pressure

Although appreciable increases in membrane thickness have not been observed at
clinically relevant doses of anaesthetic gases, it has been demonstrated that membranes
do expand laterally in the presence of anaesthetic gases (32). This study found that
narcotic agents such as nitrous oxide have an affinity for lipid monolayers, and that inert
gases at partial pressures sufficient to bring about the observed clinical effects of inert gas
narcosis should act at lipoprotein-water interfaces to cause a decrease in surface tension
of 0.39 dynes/cm (19, 32). Work by Bennett et al. was able to confirm that inert gases do
indeed penetrate lipid monolayers and affect surface tension as Clements and Wilson

127
suggested (18). Exactly how these changes could affect anaesthesia is not well
understood, but it is believed that these changes in surface tension alter the function of
the ion receptors and channels involved in synaptic transmission (18, 19, 32).
Other work on membrane model systems suggested that anaesthetic gases may
also alter ion permeabilities. While examining cation permeability in membrane model
systems, Bangham et al. found that n-alkyl alcohols, chloroform and ether result in a
transient, reversible increase in membrane cation permeability (10). Inert gases behave
the same way. Bennett and Hayward were able to demonstrate this by examining in vivo
cerebrospinal fluid (CSF) levels of sodium, potassium and chloride while measuring
auditory evoked potentials in cats. They found a significant decrease in CSF sodium and
chloride, as well as the amplitude of cortical auditory evoked potentials, in animals
compressed to 11 ATA breathing a mix of 80% nitrogen/20% oxygen or 80% argon/20%
oxygen when compared to breathing 80% helium/20 % oxygen at 11 ATA or room air at
ambient pressure (17). This is further supported by studies by Johnson and Miller as well
as by Galey and van Nice (53, 64). Johnson and Miller found that when liposomes were
exposed to butanol, ether and nitrogen in doses which would be just sufficient to abolish
the righting reflex in newts, an increase in the permeability for potassium and rubidium
was observed. An application of 152 ATA of pressure was required to counterbalance
the permeability changes (64). Galey and van Nice found that pressures of nitrogen up to
88 ATA stimulate active sodium efflux and potassium influx across the red blood cell
membrane, and that the effect is abolished by ouabain (53). They also showed that
hyperbaric pressures of the non-narcotic gas helium, rather than nitrogen, tended to
inhibit active sodium and potassium transport (53). Other work by this group using rat
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brain synaptosomes showed that hyperbaric pressures of argon would stimulate
potassium uptake by the synaptosomes while 69 ATA of helium or hydrostatic pressure
inhibited the accumulation of potassium (19). This suggests that anaesthesia and narcosis
may be the downstream product of gases dissolving into the membrane at various sites,
altering ion conduction, and thus synaptic conduction, and ultimately consciousness.
More recently, Abraini modified this multi-site expansion model based on results
obtained from human trials using hydrogen as a compression gas. He proposed a
theoretical reconsideration of the interaction between inert gases at hyperbaric pressure,
and the effects of pressure itself. According to this hypothesis, narcotic gas and pressure
act at different hydrophobic sites and narcosis occurs when a critical level of expansion is
reached at some cellular hydrophobic site in the central nervous system (1, 19). As far as
light inert gases are concerned, all narcotic gases act at a common hydrophobic region
through a non-specific mechanism (1, 19). This hypothesis suggests that the psychoticlike symptoms observed in humans at high pressure may be a paroxysmal symptom of
narcosis, not simply a manifestation of the high pressure nervous syndrome (HPNS), and
is a result of the sum of the individual narcotic potencies of the various inert gases in the
breathing mix (1). This hypothesis was tested mathematically against various lipid
solubility theories of inert gas narcosis and was found to be sound (1). This suggests that,
depending on the environmental parameters (breathing mix, pressure), symptoms of inert
gas narcosis or HPNS appear when a critical imbalance is reached between the narcotic
actions of inert gas and the actions of pressure, which tend to reverse narcosis, on their
respective hydrophobic sites (1, 19). Accordingly, inert gas narcosis and HPNS can
antagonize each other or can occur simultaneously (1, 19).
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Given the understanding that inert gas narcosis was somehow connected to
changes in synaptic conduction in the CNS, some researchers began to investigate
changes in neurotransmitters with hyperbaric exposure. Changes in levels of dopamine
and norepinephrine have been observed by several groups, but whether an increase or
decrease is observed seems to depend on what area of the brain is under investigation
rather than the pressure applied (9, 77, 100). For instance, in the hypothalamus, dopamine
and norepinephrine were shown to be decreased in response to 100 ATA trimix
(helium/nitrogen/oxygen) and to 20 ATA nitrogen/oxygen mixtures, but were increased
in the caudate nucleus (19, 77). Unfortunately these changes may not have anything to do
with inert gas narcosis. Rostain and Forni were able to demonstrate a similar increase in
striatal dopamine release in response to 90 ATA helium/oxygen mixture, 90 ATA
helium/nitrogen/oxygen mixture (5% nitrogen), and 90 ATA helium/hydrogen/oxygen
mixture (66% hydrogen) (19, 100). These mixes should have quite different narcotic
potencies, but appeared to cause the same change in dopamine levels. These changes
were attributed to, and are likely due to pressure alone, not narcosis (100). Balon et al.,
while also looking at striatal dopamine release, found a 20% decrease in dopamine
release in rats exposed to 30 ATA breathing a nitrogen/oxygen mix (9). This suggests
that neurotransmitter release in response to hyperbaric exposure and inert gases is quite
complex. It would appear that exposure to low pressures breathing a mixture of
nitrogen/oxygen decreases striatal dopamine release, while exposure to high pressures
breathing a helium/oxygen mixture increases dopamine release. Unfortunately it is very
difficult to separate out the effects of the inert gas from the effects of pressure per se
because gases with high narcotic potency will result in unconsciousness at high pressures.
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Thus, in order to expose an in vivo preparation to high pressures, helium must be used as
a diluent gas if any sort of behavioural observations are to be made. So long as gas
pressure is used to generate a hyperbaric exposure it will remain near-impossible to
distinguish the effects of high-pressure helium from those of pressure per se. Nonetheless
it would appear that there are consistent, reproducible changes in dopamine release in
response to hyperbaric exposure. This suggests that neurotransmission is likely altered
under hyperbaric conditions and may offer a partial explanation of inert gas narcosis.
Other work has suggested that nitric oxide may play a role in narcosis. Vjotosh et
al. found that when rats were compressed to 41 ATA breathing air, they showed
alterations in motor activity at 5-12 ATA, ataxia at 10-34 ATA, and side body position at
26-41 ATA. These were taken as signs of nitrogen narcosis. When treated with the nitric
oxide synthase inhibitors L-NAME or 7-NI, the above mentioned signs were abolished or
attenuated (19, 114). While interesting, these results must be taken with a grain of salt.
Air breathing at pressures greater than 10 ATA makes acute oxygen toxicity a serious
risk. Since seizures are one of the symptoms of acute oxygen toxicity, the indicators that
this group used as signs of narcosis may make narcosis and oxygen toxicity difficult to
distinguish.
Protein/Metabolic Hypotheses
Research attention is now focussing on the possibility of direct interactions
between inert and anaesthetic gases and proteins, lipoproteins, and other hydrophobic
sites within the cell (2, 48-51). Much of this evidence comes from the anaesthesia
community and the study of volatile, inhaled anaesthetics in general. If inert gas narcosis
was solely a matter of gas dissolving in lipid membranes it would be expected that the
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onset of narcotic effects would be linearly related to the rate of increase in pressure (19).
The finding that this relationship was, in fact, sigmoidal suggests that the inert gas
molecules are interacting with protein receptors directly and act as allosteric modulators
of their activity (2, 19). The idea that the mechanism underlying anaesthesia involves an
interaction with proteins is not new. This was first proposed by Claude Bernard in 1875
(20). He came to this conclusion based on the way some anaesthetic potencies deviated
from that which would be predicted from their lipid solubility alone, combined with the
understanding that many proteins contain small hydrophobic domains which would allow
for interactions with small, hydrophobic compounds (20, 41). Unfortunately the
interactions between proteins and narcotic compounds appear to be very short-lived, on
the order of a millisecond or less (41). Conventional binding assays are simply unable to
measure such low affinity binding (41).
Since direct measurements of binding are not possible, those interested in
studying protein-based mechanisms of anaesthesia and narcosis have resorted to
molecular pharmacology and assays of protein activity in various in vitro preparations
(41). These techniques have evaluated possible protein/anaesthetic interactions based on
two criteria: ‘plausibility’ and ‘sensitivity’. Plausibility refers to the degree to which
changes in protein activity observed in the preparation lines up with our preconceptions
of anaesthetic mechanisms (41). For instance, it is believed that anaesthesia and narcosis
are products of CNS depression; therefore the observation that an anaesthetic inhibits
proteins involved in excitatory synaptic transmission, or activates proteins involved in
inhibitory synaptic transmission would fit the ‘plausibility’ criterion. The sensitivity
criterion would come in to play in order to evaluate the dose-dependence of the observed
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changes in protein activity. This criterion would be satisfied if the observed in vitro EC50
is similar to the observed clinical EC50. Plausibility, in this sense, is certainly a very
fuzzy concept. Our understanding of the neurophysiology of consciousness is very
limited. Consequently our understanding of altered states of consciousness is even more
limited, so plausibility is very much open to the subjective interpretation of the
investigator.
Inhalational anaesthetics including inert gases have been investigated in several
different in vitro systems and have been found to alter the functions of many enzymes,
receptors, transporters, ligand- and voltage-gated ion channels, as well as structural
proteins (42). A growing body of evidence suggests that inhalational general anaesthetics
work through interactions with proteins, particularly post-synaptic ligand-gated ion
channels (6, 34, 37, 49, 51, 119). These interactions fit well, not only with the plausibility
criterion, but with the sensitivity criterion; the doses observed to have appropriate in vitro
effects are very similar to clinical doses used to produce general anaesthesia (60). The
idea that inhaled anaesthetics exert their effects through modulation of inhibitory postsynaptic ligand-gated ion channels is interesting. When activated by the binding of the
appropriate ligand (ex. GABA) these chloride channels open and chloride flows into the
cell causing a hyperpolarization and decreasing the likelihood of action potential
propagation (41). Clinically effective concentrations of several inhaled anaesthetics have
been demonstrated to potentiate both GABA- and glycine-modulated chloride currents in
vitro (85, 86).
Several problems still exist with the hypothesis that inhaled anaesthetics operate
through the modulation of ligand-gated ion channels such as the GABA receptor. First, in
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vitro, it has been shown that at high doses of anaesthetic drugs (above 1 mM), GABAA
activity tends to be inhibited, yet clinically, increasing anaesthetic doses lead to deeper
anaesthesia, not reversal (85, 86). Second, in neonatal rodents, chloride gradients are
reversed, thus GABA acts as an excitatory neurotransmitter, but inhaled anaesthetics are
still effective in these animals, although slightly higher doses are required (87). Third, if
the anxiolytic effect of benzodiazepines is a result of potentiation of the GABAA
receptor, inhaled anaesthetics must act through a different mechanism since their effect is
decidedly non-anxiolytic (41). The early stages of general anaesthesia induced with
inhaled anaesthetics produces an excitatory phase, which can produce seizure-like
activity, whereas benzodiazepines prevent seizures (41). Fourth, chloride channel
blockers and GABAA antagonists have only minimal effects on the potency of inhaled
anaesthetics (57, 98). This evidence suggests that, although volatile anaesthetics can
modulate ligand-gated chloride channel activity at clinically relevant concentrations in
vitro (and possible in vivo), it is unclear how this effect is related to anaesthesia.
Anaesthesia may be a product, not of interaction with a single protein, but of
interaction with multiple molecular targets. This is suggested by the observations that
inhaled anaesthetic agents affect multiple proteins, as well as the fact that multiple
anaesthetics with diverse molecular structures all produce the same end result:
anaesthesia (41). There is evidence for unique binding sites for several inhaled
anaesthetics on a single target, but it seems unlikely that a single molecular target would
have specific binding sites for diverse molecular structures ranging from xenon to nitrous
oxide to sevoflurine (40, 56). Other evidence suggests that there may be a single,
selective target for each anaesthetic, but it seems unlikely that all these molecular targets
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would lead to the same end result – anaesthesia (36, 95). This finding does, however,
provide reasonable grounds to believe that interactions with multiple molecular targets
may converge to produce the single effect of anaesthesia (41).
It should be remembered that specific interaction with a protein target and
multiple sites of action are not mutually exclusive. It is well understood that ATP,
oxygen, and calcium all bind selectively with multiple different targets. Volatile
anaesthetics have also been shown to bind selectively with multiple different targets,
including firefly luciferase, serum albumin, myoglobin, adenylate kinase, haloalkane
dehalogenase and T4 lysozyme (21, 47, 94, 102, 104, 113). Even more compelling
evidence comes from autoradiograms of rat brain slices probed with a radiolabelled
halothane derivative. The radiographs revealed widespread binding throughout the brain
whose distribution did not match that of any known receptor or channel (39), see Figure
3. Furthermore, the binding was reduced to background levels in the presence of a 10fold excess of unlabelled halothane (39). When extracted and separated, multiple brain
proteins were found to be specifically labelled in a saturable and stoichiometric manner
with estimated affinities near the clinical EC50 (38).
The nature of the interaction between anaesthetics and proteins may lie in the
structure of proteins themselves. It is understood that proteins fold into complex 3dimensional structures which are not solid, but rather contain cavities. These cavities are
believed to be critical structural elements in protein function as they introduce areas of
instability which allow conformational changes to take place (24, 112). These cavities
within the hydrophobic core of proteins provide plausible binding sites consistent with
the observation that anaesthetic potency is correlated with lipid solubility. That potent
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anaesthetics exhibit weak polarity is also consistent with the hypothesis that they bind in
protein cavities as most cavities are also weakly polar (41). The elements of protein
secondary structure which form the surface of these cavities could also provide an
explanation for the weak stereoselectivity observed with some anaesthetics such as
isoflurane (51, 76). Occupancy of these cavities by anaesthetic molecules could affect
anaesthesia by limiting the motion that underlies protein activity (41). Studies have
indicated that occupancy of cavities by small, hydrophobic molecules does reduce protein
motion (24, 112). This is clearly a multiple target hypothesis, and nicely reconciles
results form binding and functional studies (41).
Xenon
Thus far the terms ‘inert gas narcosis’ and ‘anaesthesia’ have been, to a degree,
used interchangeably. This is due to both the hypothesis that all anaesthetics act through
the same basic mechanism, as well as the observation that inert gas narcosis resembles
early stages of anaesthesia and that inert gases can produce general anaesthesia if
delivered at sufficient partial pressures. The inert gas xenon exemplifies much of this
overlap and somewhat loose use of terminology. Xenon is an inert gas whose narcotic
potency is so high that it can be used as a general anaesthetic at 1 ATA (92). If it can be
assumed that inert gas narcosis exists as a single condition, regardless of the inert gas in
question (to a large extent the research community has already done so in order to try to
separate narcotic effects from pressure effects), what is understood about the mechanism
of xenon anaesthesia can be extended to all inert gas narcosis and gas anesthesia (2, 9, 16,
53, 92, 99).
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Investigations into the mechanism of action of xenon gas anaesthesia present a
microcosm of investigations into the mechanism of action of the entire scope of
inhalational anaesthesia. Both lipid (membrane) and direct interaction with protein
hypotheses abound. In support of the membrane hypothesis, there is evidence that xenon
can interact with lipid bilayers and change surface tension, bilayer volume, and pressure
within the bilayer (110, 117). There is also evidence to suggest that the xenon dissolved
in the membrane, despite its high lipid solubility, may not reside within the central core
or tail region of the membrane. Rather, xenon may preferentially migrate to the
amphiphilic region around the head groups after dissolving in the membrane (26, 117).
This accumulation of xenon molecules in the membrane is believed to affect the structure
and function of proteins embedded within the membrane (8, 41, 110). In particular, it is
believed that changes in surface tension and pressure within the membrane result in
conformational changes in ion channels within the synaptic terminals of neurons,
resulting in decreased conduction, leading to anaesthesia (8, 26, 41, 110, 117).
The greatest criticism levelled against much of the work done on the basis of the
lipid hypothesis of narcosis, be that in vitro or in silico work, is the fact that most of these
studies are done using dipalmitoylphosphatidylcholine (DPPC) bilayers as a membrane
system (41). DPPC is an easily obtained egg yolk phospholipid which contains no double
bonds to oxidize and readily forms into a biologically relevant liquid crystalline bilayer
(41). Unfortunately it is also far too simple a system to accurately model a biological
membrane. Living plasma membranes, especially those of neurons, contain a highly
heterogeneous mixture of lipids, some saturated, some unsaturated, some charged, some
neutral, as well as cholesterol (41). Biological membranes also contain various proteins
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which make up approximately 50% of the mass of the membrane (41). In addition, it is
now understood that the inner and outer leaflets of biological membranes are composed
of different phospholipids and that the membrane is arranged laterally into distinct areas
known as lipid rafts, which are composed of distinct lipids and proteins (23, 41). For
example, nicotinic acetylcholine receptors in nerve and muscle cells require the presence
of cholesterol and anionic phospholipids in their immediate vicinity in order to function
properly (22, 41). The simple membrane systems often used experimentally are a poor
approximation of biological membranes and thus their findings for the mechanism of
narcosis must be taken with a grain of salt, as it were. At the same time, they do
demonstrate that it is plausible that the membrane is, at lease in part, responsible for the
mechanism of narcosis.
There is also evidence that xenon anaesthesia/narcosis may be a product of
interaction with proteins. Whereas most general anaesthetics have been shown to enhance
the inhibitory activity of GABAA receptors, xenon seems to have little or no effect on
them (46, 49). Instead it appears that xenon inhibits the excitatory action of N-methyl-Daspartate (NMDA) receptors and, to lesser extents, neuronal nicotinic receptors and
TREK-1 two-pore K+ channels (34, 46, 58, 118). Interestingly, the NMDA receptor, a
subtype of the glutamate receptor, is believed to be involved in learning, memory, and the
perception of pain, which could explain xenon’s attractive pharmacological properties
(46, 96). This appears to be a non-competitive inhibition of the NMDA receptor, so
xenon should strongly inhibit neuronal transmission even in the presence of high
glutamate concentrations in the synaptic cleft (46). This inhibition of the NMDA receptor
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by xenon goes a long way toward explaining the analgesic and amnesic effects of xenon
(46).
X-ray crystallographic studies have also been performed in order to examine how
and where xenon is interacting with various proteins. Unfortunately, membrane bound
proteins such as the NMDA receptor are difficult to crystallize, so xenon has not been
crystallized with the protein actually believed to be its target, but with soluble surrogate
proteins. Xenon has been crystallized with urate oxidase, a prototype of various
intracellular globular proteins, and with annexin V, a protein with structural and
functional characteristics which allow it to be considered a prototype of the NMDA
receptor (33, 34, 54). A single xenon molecule was found to bind to both of these
proteins in a flexible, hydrophobic cavity (34). This is consistent with both the
hydrophobicity of xenon and with the previous hypothesis that anaesthetic molecules
exert their effect by binding proteins in these hydrophobic cavities (41). This suggests
that it is plausible that xenon binds with the NMDA receptor, but that it is also capable of
binding to a wide range of soluble intracellular proteins, consistent with the hypothesis
that anaesthesia/narcosis is likely the ultimate product of multiple drug/protein
interactions (41).
Other anaesthetic compounds which are believed to operate primarily by
inhibiting NMDA receptor signalling, such as nitrous oxide and ketamine, have been
observed to increase both global and regional cerebral metabolism in humans (66, 68, 69,
83, 90). Thus it would be expected that, if the anaesthetic action of xenon also operates
primarily by inhibiting the NMDA receptor, that it should also increase both global and
regional cerebral metabolism (97). Cerebral metabolic rates can be examined using
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positron emission tomography (PET) and such studies have been performed (97).
Because most general anaesthetics depress cerebral metabolism relative to conscious
states, xenon anaesthesia was examined relative to propofol anaesthesia (3-5, 66).
Contrary to expectations, it was found that xenon anaesthesia depressed cerebral
metabolism both globally and regionally in the orbitofrontal, frontomedial,
temporomedial, occipital, dorsolateral frontal, and lateral temporal cortices and thalamus
(97). This suggests strongly that the mechanism of xenon anaesthesia/narcosis is not
simply the inhibition of NMDA receptors.
Conclusion
Inert gasses clearly have physiological effects. To date, some work has been done
to examine the effects of inert gasses on neurons, nerve conduction and consciousness,
and a picture of how inert gases function as anaesthetics is beginning to emerge. The idea
that inert gas narcosis can be reduced to a single cause is likely incorrect. The symptoms
displayed vary widely, not only between different individuals, but also between different
exposures for the same individual. The conditions required to bring about the onset of
inert gas narcosis (ambient pressure, gas mix being breathed, temperature, psychological
factors) also appear to vary widely. Hypotheses focusing exclusively on either cell
membranes or protein interactions do not appear to tell the whole story. At this point in
the research it would appear that there are elements of truth in both of these hypotheses.
Continued research into both inert gas narcosis, and the mechanisms of general
anaesthesia, particularly mechanisms pertaining to inhaled anaesthetics, are likely to
further understanding of both conditions. The time may be nearing when, in order to truly
understand the mechanisms of inert gas narcosis and general anaesthesia, hypotheses will
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need to be able to bring together understanding which has been gained from both lipidand protein-based models in order to construct a single model which can explain all the
observations.
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Gas

Molecular
Weight

Volume

Lipid
Solubility at
37°C

Oil:water
partition
coefficient

Helium
4
2.370
0.015
1.70
Neon
20
1.709
0.019
2.07
Hydrogen
2
2.661
0.040
3.10
Nitrogen
28
3.913
0.067
5.25
Argon
40
3.218
0.140
5.32
Krypton
83.7
3.978
0.430
9.60
Xenon
131.3
3.105
1.700
20.00
Figure 1. Narcotic potencies and physical properties of simple gasses. From (75).

Relative
narcotic
potency
0.23
0.28
0.55
1.00
2.33
7.14
25.64

Figure 2. The critical volume hypothesis. Molecules of narcotic gases disolve in the cell membrane
and cause it to swell. When the membrane reaches a certain volume narcosis is produced. Pressure
reverses this narcotic effect by compressing the membrane. From (99).
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Figure 3 Autoradiogram of rat brain section photoaffinity labeled with radioactive halothane.
Degree of halothane binding is indicated by level of darkness; no other staining has been applied to the
section. The binding shows little regional preference and is reduced to near-background levels in the
presence of a tenfold excess of unlabeled halothane. The dramatic inhibition of labeling by non-radioactive
halothane indicates that most halothane binding is saturable and specific, showing that many proteins could
be involved in anesthetic action. From (39)
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